Novel double-stranded sirna, conjugate thereof, and use thereof

By using novel double-stranded siRNA and its conjugates, the expression of HBV gene is specifically inhibited through RNA interference, which solves the problems of drug resistance and toxicity of existing hepatitis B treatment drugs and achieves effective treatment of hepatitis B.

WO2024245381A1PCT designated stage expired Publication Date: 2024-12-05SUNSHINE LAKE PHARMA CO LTD

Patent Information

Application Number
PCT/CN2024/096557
Authority / Receiving Office
WO · WO
Patent Type
Applications
Current Assignee / Owner
Priority Date
2023-06-01
Filing Date
2024-05-31
Publication Date
2024-12-05

AI Technical Summary

Technical Problem

Existing hepatitis B treatments, such as interferon and nucleoside analogs, suffer from drug resistance and adverse reactions, making it difficult to effectively block the generation and replication of HBV.

Method used

To develop a novel double-stranded siRNA and its conjugates that specifically inhibit HBV gene expression via RNA interference, comprising modified sense and antisense strands, and using modified nucleotides and conjugate groups to enhance gene expression inhibition activity and reduce toxicity.

Benefits of technology

This study achieved highly efficient inhibition of HBV gene expression, reduced drug toxicity, and provided a new treatment method for hepatitis B.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure PCTCN2024096557-FTAPPB-I100001
    Figure PCTCN2024096557-FTAPPB-I100001
  • Figure PCTCN2024096557-FTAPPB-I100002
    Figure PCTCN2024096557-FTAPPB-I100002
  • Figure PCTCN2024096557-FTAPPB-I100003
    Figure PCTCN2024096557-FTAPPB-I100003
Patent Text Reader

Abstract

The present invention provides a double-stranded siRNA, a conjugate thereof, or a salt thereof, and also relates to a use of the double-stranded siRNA and the conjugate thereof in the preparation of a drug for treating and / or preventing hepatitis B diseases. In addition, the present invention also relates to a novel compound, and uses of the compound in the study of raw materials for the solid-phase synthesis of DNA nucleotides, raw materials for the synthesis of siRNA drugs, and siRNA drugs, the study of gene function, and / or whole gene library screening, especially a use of the compound as an oligonucleotide intercalating group in raw materials for the synthesis of double-stranded siRNA drugs.
Need to check novelty before this filing date? Find Prior Art

Description

A novel double-stranded siRNA, its conjugate and its use Technical Field

[0001] The present invention belongs to the field of small nucleic acid drugs, and the purpose of the present invention is to provide a novel double-stranded siRNA, its conjugate and its use. The present invention also provides the use of the double-stranded siRNA and its conjugate in the preparation of a drug for treating and / or preventing hepatitis B disease. In addition, the present invention also relates to a novel compound, and the application (use) of the compound in the raw materials for solid-phase synthesis of DNA nucleotides, the synthetic raw materials for oligonucleotide drugs, the synthetic raw materials for siRNA drugs, siRNA drug research, gene function research and / or the screening of whole gene libraries, especially the use as the synthetic raw materials for the double-stranded siRNA drug of the present invention. In addition, the present invention also relates to a novel nucleotide residue, and its application in siRNA drug research, gene function research and / or the screening of whole gene libraries, and its application as an oligonucleotide intercalating group. Background Art

[0002] Hepatitis B (also known as HBV or HBV) is a serious infectious disease posing a global threat, particularly in China. Currently, the two most recognized classes of HBV treatments are interferon and nucleoside analogs. However, these two classes of drugs have numerous drawbacks, including the development of drug resistance and limited use. For example, interferon is prone to adverse reactions, while nucleoside analogs are susceptible to drug resistance and relapse after discontinuation. Therefore, if viral gene expression could be silenced at the genetic level, blocking HBV production and replication, thereby fundamentally reducing viral replication and infection of liver cells, it would undoubtedly be the most ideal treatment for HBV. Small interfering nucleic acids, also known as small interfering RNA or short interfering RNA (siRNA), can inhibit or block the expression of any target gene of interest (e.g., genes that cause diseases such as cancer) in a sequence-specific manner based on the mechanism of RNA interference (RNAi), thereby achieving the goal of treating the disease.

[0003] RNA interference (RNAi) is a phenomenon in which double-stranded RNA (dsRNA) molecules shut down or silence homologous gene expression at the mRNA level. RNAi, also known as gene knockdown or gene silencing, is a typical post-transcriptional gene regulation method, also known as post-transcriptional gene silencing (PTGS). The earliest reports of RNAi appeared in 1990, when two different research groups simultaneously reported RNAi in transgenic plants. Subsequently, RNAi was observed in nearly all eukaryotic organisms, including nematodes, fruit flies, zebrafish, and mice. In 1999, Hamilton and Baulcombe detected RNA fragments of 21-25 nucleotides in plants that exhibited RNAi. These RNA fragments were shown to be essential for RNAi and were termed small interfering nucleic acids (siRNAs). Double-stranded siRNAs form an RNA-induced silencing complex (RISC) with relevant cell-derived enzymes and proteins. During RNA interference, the sense strand in the double-stranded siRNA is excluded from the complex, and the antisense strand guides RISC to bind to the homologous site of the target mRNA. The target mRNA is then degraded by ribonuclease III in the complex, thereby shutting down the expression of the target gene.

[0004] Summary of the Invention

[0005] The present invention aims to provide a novel double-stranded siRNA, its conjugates, its salts, and their uses, and specifically relates to the use of the double-stranded siRNA and its conjugates of the present invention in the preparation of a medicament for treating and / or preventing hepatitis B. Furthermore, the present invention relates to a novel compound and its use as a raw material for solid-phase synthesis of DNA nucleotides, a raw material for the synthesis of siRNA drugs, siRNA drug research, gene function research, and / or screening of whole gene libraries, particularly as a raw material for the synthesis of the double-stranded siRNA drugs of the present invention. Furthermore, the present invention relates to a novel nucleotide residue and its use in siRNA drug research, gene function research, and / or screening of whole gene libraries, as well as its use as an intercalating group in oligonucleotides. The double-stranded siRNA and its conjugates of the present invention have high gene expression inhibitory activity and / or low toxicity against HBV.

[0006] In one aspect, the present invention relates to a double-stranded siRNA, a conjugate thereof, or a salt thereof, wherein the double-stranded siRNA comprises a sense strand and an antisense strand, and the double-stranded siRNA comprises one or more Y, wherein Y is Each nucleotide and Y in the double-stranded siRNA is independently modified or unmodified. Optionally, the Y can be at any position in the double-stranded siRNA.

[0007] In some embodiments of the double-stranded siRNA, its conjugate or salt thereof of the present invention, the double-stranded siRNA comprises 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10 Ys.

[0008] In some embodiments of the double-stranded siRNA, its conjugate or salt thereof of the present invention, the double-stranded siRNA comprises 1, 2, 3, 4 or 5 Ys.

[0009] In some embodiments of the double-stranded siRNA, its conjugate, or salt thereof of the present invention, the antisense strand comprises a sequence as shown in 5'-UGUGAAGCGAAGUGCACACUU-3' (SEQ ID NO: 40), or a sequence in which one or more nucleotide residues are replaced with Y in the sequence as shown in SEQ ID NO: 40; wherein each nucleotide and Y in the antisense strand are independently modified or unmodified, and the length of the antisense strand does not exceed 23 nucleotides, wherein Y has the meaning described herein. Optionally, the Y replacement occurs at any position in the sequence as shown in SEQ ID NO: 40.

[0010] In some embodiments of the double-stranded siRNA, its conjugate, or salt thereof of the present invention, the sense strand comprises a sequence as shown in 5'-GUGUGCACUUCGCUUCACA-3' (SEQ ID NO: 20), or a sequence in which one or more nucleotide residues are substituted with Y in the sequence as shown in SEQ ID NO: 20, wherein each nucleotide and Y in the sense strand are independently modified or unmodified, and the length of the sense strand does not exceed 23 nucleotides. Optionally, the Y substitution occurs at any position in the sequence as shown in SEQ ID NO: 20.

[0011] In some embodiments of the double-stranded siRNA, its conjugate or salt thereof of the present invention, 70%, 75%, 80%, 85%, 90% or more of the nucleotides and Y in the sense strand or antisense strand of the double-stranded siRNA are modified.

[0012] In some embodiments of the double-stranded siRNA, its conjugate or salt thereof of the present invention, 70%, 75%, 80%, 85%, 90% or more of the nucleotides and Y in the sense strand and the antisense strand of the double-stranded siRNA are modified.

[0013] In some embodiments of the double-stranded siRNA, its conjugate or salt thereof of the present invention, each nucleotide and Y in the double-stranded siRNA is modified.

[0014] In some embodiments of the double-stranded siRNA, its conjugate or its salt of the present invention, the modification is selected from at least one of the following: 2'-methoxy modification, 2'-methoxyethyl modification, 2'-fluoro modification, thiophosphate linkage, 2'-deoxy modification, 2'-amino modification, locked nucleic acid modification, unlocked nucleic acid modification, ethylene glycol nucleic acid modification and 5'-vinyl phosphate modification.

[0015] In some embodiments of the double-stranded siRNA, its conjugate or salt thereof of the present invention, the sense strand comprises a sequence in which 0, 1, 2, 3, 4 or 5 nucleotide residues are replaced with Y in the sequence as shown in SEQ ID NO: 20, wherein each nucleotide and Y in the sense strand are independently modified or unmodified.

[0016] In some embodiments of the double-stranded siRNA, its conjugate, or a salt thereof of the present invention, the sense strand comprises a sequence in which one nucleotide residue is replaced by Y in the sequence shown in SEQ ID NO: 20.

[0017] In some embodiments of the double-stranded siRNA, its conjugate, or its salt of the present invention, the antisense strand comprises a sequence in which 0, 1, 2, 3, 4, or 5 nucleotide residues are substituted with Y in the sequence as shown in SEQ ID NO: 40, wherein each nucleotide and Y in the antisense strand are independently modified or unmodified. In some embodiments of the double-stranded siRNA, its conjugate, or its salt of the present invention, the antisense strand comprises a sequence in which 1 nucleotide residue is substituted with Y in the sequence as shown in SEQ ID NO: 40.

[0018] In some embodiments of the double-stranded siRNA, its conjugate or salt thereof of the present invention, the Y substitution occurs at positions 1 to 19 of the 5' end of the sequence as shown in SEQ ID NO: 20 (i.e., the Y substitution optionally occurs at position 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18 or 19 of the 5' end of the sequence as shown in SEQ ID NO: 20).

[0019] In some embodiments of the double-stranded siRNA, its conjugate or salt thereof of the present invention, the Y substitution occurs at position 1 to 21 of the 5' end of the sequence as shown in SEQ ID NO: 40 (i.e., the Y substitution optionally occurs at position 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20 or 21 of the 5' end of the sequence as shown in SEQ ID NO: 40).

[0020] In some embodiments of the double-stranded siRNA, its conjugate or salt thereof of the present invention, the sense strand comprises a sequence in which 0, 1, 2, 3, 4 or 5 nucleotide residues are replaced with Y in the sequence as shown in 5'-g u guGcACUucgcuucaca-3' (SEQ ID NO: 19), wherein each nucleotide and Y of the sense strand are independently modified or unmodified, and the Y replacement occurs at positions 1 to 19 of the 5' end of the sequence as shown in SEQ ID NO: 19 (i.e., the Y replacement optionally occurs at position 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18 or 19 of the 5' end of the sequence as shown in SEQ ID NO: 19), and the length of the sense strand does not exceed 23 nucleotides.

[0021] In some embodiments of the double-stranded siRNA, its conjugate or salt of the present invention, the antisense strand comprises a sequence in which 0, 1, 2, 3, 4 or 5 nucleotide residues are replaced with Y in the sequence as shown in 5'-u●G●ugaAgCGaaguGcAcac●u●u-3' (SEQ ID NO: 36), wherein each nucleotide and Y of the antisense strand are independently modified or unmodified, and the Y replacement occurs at positions 1 to 21 of the 5' end of the antisense strand SEQ ID NO: 36 (i.e., the Y replacement optionally occurs at position 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18 or 19 of the 5' end of the sequence as shown in SEQ ID NO: 36), and the length of the antisense strand does not exceed 23 nucleotides.

[0022] In some embodiments of the double-stranded siRNA, its conjugate or salt thereof of the present invention, the antisense strand comprises a sequence in which 0, 1, 2, 3, 4 or 5 nucleotide residues are substituted with Y in the sequence as shown in 5'-u●G●uga(Agn)gCGaaguGcAcac●u●u-3' (SEQ ID NO: 33), wherein each nucleotide and Y of the antisense strand are independently modified or unmodified, and the Y substitution occurs at positions 1 to 21 at the 5' end of the sequence as shown in SEQ ID NO: 33 (i.e., the Y substitution optionally occurs at position 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18 or 19 at the 5' end of the sequence as shown in SEQ ID NO: 33)), and the length of the antisense strand does not exceed 23 nucleotides.

[0023] Unless otherwise specified, in the context of the present invention, capital letters C, G, U, and A represent the base composition of natural nucleotides; lowercase letters c, g, u, and a respectively represent that the 2-position of the ribose on the nucleotide represented by the corresponding capital letter is modified by methoxy; the underline ___ below the capital letter represents that the 2-position of the ribose on the nucleotide represented by the letter is modified by fluorine; Agn is adenosine-ethylene glycol nucleic acid; the spacer "●" indicates that the two nucleotide residues adjacent to the spacer "●" are connected by a phosphorothioate group; Y is

[0024] In some embodiments of the double-stranded siRNA, conjugate or salt thereof of the present invention, the sense strand comprises one of the following nucleotide sequences:

[0025] SEQ ID NO:1, SEQ ID NO:2, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:6, SEQ ID NO:7, SEQ ID NO:8, SEQ ID NO:9, SEQ ID NO:10, SEQ ID NO:11, SEQ ID NO:12, SEQ ID NO:13, SEQ ID NO:14, SEQ ID NO:15, SEQ ID NO:16, SEQ ID NO:17, SEQ ID NO:18, SEQ ID NO:19 and SEQ ID NO:21;

[0026] The length of the sense strand does not exceed 23 nucleotides.

[0027] In some embodiments of the double-stranded siRNA, conjugate or salt thereof of the present invention, the antisense strand comprises one of the following nucleotide sequences:

[0028] SEQ ID NO:22, SEQ ID NO:23, SEQ ID NO:24, SEQ ID NO:25, SEQ ID NO:26, SEQ ID NO:27, SEQ ID NO:28, SEQ ID NO:29, SEQ ID NO:30, SEQ ID NO:31, SEQ ID NO:32, SEQ ID NO:33, SEQ ID NO:34, SEQ ID NO:35, SEQ ID NO:36, SEQ ID NO:37, SEQ ID NO:38 and SEQ ID NO:39;

[0029] The antisense strand is no more than 23 nucleotides in length.

[0030] In some embodiments of the double-stranded siRNA, its conjugate or salt of the present invention, the double-stranded siRNA comprises one of the following:

[0031] A sense strand comprising the nucleotide sequence set forth in SEQ ID NO: 15 and an antisense strand comprising the nucleotide sequence set forth in SEQ ID NO: 25, wherein the sense strand and antisense strand are each independently no longer than 23 nucleotides;

[0032] A sense strand comprising the nucleotide sequence of SEQ ID NO: 17 and an antisense strand comprising the nucleotide sequence of SEQ ID NO: 25, wherein the sense strand and antisense strand are each independently no longer than 23 nucleotides;

[0033] A sense strand comprising the nucleotide sequence set forth in SEQ ID NO: 15 and an antisense strand comprising the nucleotide sequence set forth in SEQ ID NO: 26, wherein the sense strand and antisense strand are each independently no longer than 23 nucleotides;

[0034] A sense strand comprising the nucleotide sequence set forth in SEQ ID NO: 16 and an antisense strand comprising the nucleotide sequence set forth in SEQ ID NO: 26, wherein the sense strand and antisense strand are each independently no longer than 23 nucleotides;

[0035] A sense strand comprising the nucleotide sequence of SEQ ID NO: 17 and an antisense strand comprising the nucleotide sequence of SEQ ID NO: 26, wherein the sense strand and antisense strand are each independently no longer than 23 nucleotides;

[0036] A sense strand comprising the nucleotide sequence of SEQ ID NO: 15 and an antisense strand comprising the nucleotide sequence of SEQ ID NO: 27, wherein the sense strand and antisense strand are each independently no longer than 23 nucleotides;

[0037] A sense strand comprising the nucleotide sequence set forth in SEQ ID NO: 16 and an antisense strand comprising the nucleotide sequence set forth in SEQ ID NO: 27, wherein the sense strand and antisense strand are each independently no longer than 23 nucleotides;

[0038] A sense strand comprising the nucleotide sequence set forth in SEQ ID NO: 17 and an antisense strand comprising the nucleotide sequence set forth in SEQ ID NO: 27, wherein the sense strand and antisense strand are each independently no longer than 23 nucleotides;

[0039] A sense strand comprising the nucleotide sequence of SEQ ID NO: 16 and an antisense strand comprising the nucleotide sequence of SEQ ID NO: 28, wherein the sense strand and antisense strand are each independently no longer than 23 nucleotides;

[0040] having a sense strand comprising the nucleotide sequence set forth in SEQ ID NO: 17 and an antisense strand comprising the nucleotide sequence set forth in SEQ ID NO: 28, wherein the sense strand and antisense strand are each independently no longer than 23 nucleotides; or

[0041] The sense strand comprises the nucleotide sequence shown in SEQ ID NO: 18, and the antisense strand comprises the nucleotide sequence shown in SEQ ID NO: 28, wherein the length of the sense strand and the antisense strand is each independently no more than 23 nucleotides.

[0042] In some embodiments of the double-stranded siRNA, its conjugate or salt thereof of the present invention, the double-stranded siRNA or its conjugate is selected from one of S1 to S143, S146, S147 and S150 in Table 1 of the present specification. In some embodiments of the double-stranded siRNA, its conjugate or salt thereof of the present invention, the double-stranded siRNA conjugate comprises the double-stranded siRNA and a conjugation group, that is, the double-stranded siRNA conjugate is a conjugate of the double-stranded siRNA conjugated to the conjugation group, wherein the conjugation group includes but is not limited to L-96 or DAW40007-4, and the structures of L-96 and DAW40007-4 are:

[0043] In some embodiments of the double-stranded siRNA, its conjugate, or salt thereof of the present invention, the conjugated group is conjugated to the 3' end or the 5' end of the sense strand of the double-stranded siRNA.

[0044] In some embodiments of the double-stranded siRNA, its conjugate, or salt thereof of the present invention, the conjugated group is conjugated to the 3' end of the sense strand of the double-stranded siRNA.

[0045] In some embodiments of the double-stranded siRNA, its conjugate or salt thereof of the present invention, the double-stranded siRNA is linked to the conjugated group through a phosphate group, a phosphorothioate group or a phosphate group.

[0046] On the other hand, the present invention also relates to a nucleotide residue Y having the structure:

[0047] On the other hand, the present invention also relates to a compound having a structure as shown in formula (I), or a stereoisomer, tautomer or acceptable salt of the compound as shown in formula (I),

[0048] R 1 is methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl or tert-butyl, each of which is independently optionally substituted with 1, 2, 3 or 4 substituents selected from deuterium, hydroxy, cyano, F, Cl, Br, I, methoxy, ethoxy, 1-propoxy and 2-propoxy;

[0049] Z and Y 1 are independently H, deuterium, a hydroxyl protecting group, HOC(=O)(CH2) j C(=O)-, MC(=O)(CH2) j C(═O)—, a phosphate group, a phosphorothioate group, a phosphoamido group, or a hydrogen phosphate group;

[0050] M is a solid support, preferably a hydroxyl- or amino-functionalized solid support, more preferably a resin or CPG, further preferably a macroporous resin or CPG, further preferably an aminomethyl resin, a hydroxyl resin or -NHCPG;

[0051] R is -NHR 2 or -N=CH-NR a R b ;

[0052] R 2 is an amino protecting group;

[0053] Each R a and R b are independently H or an amino protecting group, or R a 、R bTogether with the nitrogen atom to which they are attached, they form a heterocyclic group consisting of 5-6 ring atoms, wherein each heterocyclic group consisting of 5-6 ring atoms is independently optionally substituted with 1, 2, 3 or 4 substituents selected from deuterium, hydroxy, cyano, F, Cl, Br, I, methyl, ethyl, n-propyl, isopropyl, methoxy, ethoxy, 1-propoxy and 2-propoxy;

[0054] wherein each j is independently 1, 2, 3, 4 or 5.

[0055] In some embodiments of the compounds described herein, Z and Y 1 and each is independently H, deuterium, benzyloxycarbonyl, 4-nitrobenzyloxycarbonyl, 4-bromobenzyloxycarbonyl, 4-methoxybenzyloxycarbonyl, biphenylmethoxycarbonyl, 2,2,2-trichloroethoxycarbonyl, 2-(trimethylsilyl)ethoxycarbonyl, allyloxycarbonyl, chloroacetyl, trifluoroacetyl, methoxyacetyl, phenoxyacetyl, benzoyl, 2,2,2-trichloroethyl, 2-trimethylsilylethyl, 1,1-dimethyl-2-propenyl, 3-methyl-3-butenyl, allyl, p-methoxybenzyldiphenylmethyl, tetrahydrofuranyl, methoxymethyl, methylthiomethyl, benzyloxymethyl, 2,2,2-trichloroethoxymethyl, 2-(trimethylsilyl)ethoxymethyl, methylsulfonyl, p-toluenesulfonyl, C 1-12 Alkyl, C 1-12 Alkyl C(=O)-, C 1-12 Alkylsilyl, C 6-10 Aryl C 1-6 Alkyl, HOC(=O)(CH2) j C(=O)-, MC(=O)(CH2) j C(=O)-, triphenylmethyl, MMTr, DMTr, 4',4',4'-trimethoxytrityl, Among them, j, M, X, R x 、R y 、R c and R d has the meanings described in the present invention.

[0056] In some embodiments of the compounds described herein, Z and Y 1and each is independently H, deuterium, benzyloxycarbonyl, 4-nitrobenzyloxycarbonyl, 4-bromobenzyloxycarbonyl, 4-methoxybenzyloxycarbonyl, biphenylmethoxycarbonyl, 2,2,2-trichloroethoxycarbonyl, 2-(trimethylsilyl)ethoxycarbonyl, allyloxycarbonyl, chloroacetyl, trifluoroacetyl, methoxyacetyl, phenoxyacetyl, benzoyl, 2,2,2-trichloroethyl, 2-trimethylsilylethyl, 1,1-dimethyl-2-propenyl, 3-methyl-3-butenyl, allyl, p-methoxybenzyldiphenylmethyl, tetrahydrofuranyl, methoxymethyl, methylthiomethyl, benzyloxymethyl, 2,2,2-trichloroethoxymethyl, 2-(trimethylsilyl)ethoxymethyl, methylsulfonyl, p-toluenesulfonyl, C 1-10 Alkyl, C 1-10 Alkyl C(=O)-, C 1-10 Alkylsilyl, C 6-10 Aryl C 1-4 Alkyl, HOC(=O)(CH2) j C(=O)-, MC(=O)(CH2) j C(=O)-, triphenylmethyl, MMTr, DMTr, 4',4',4'-trimethoxytrityl, Among them, j, M, X, R x 、R y 、R c and R d has the meanings described in the present invention.

[0057] In some embodiments of the compounds described herein, Z and Y 1 and each independently represents H, deuterium, benzyloxycarbonyl, 4-nitrobenzyloxycarbonyl, 4-bromobenzyloxycarbonyl, 4-methoxybenzyloxycarbonyl, biphenylmethoxycarbonyl, 2,2,2-trichloroethoxycarbonyl, 2-(trimethylsilyl)ethoxycarbonyl, allyloxycarbonyl, chloroacetyl, trifluoroacetyl, methoxyacetyl, phenoxyacetyl, benzoyl, 2,2,2-trichloroethyl, 2-trimethylsilylethyl, 1,1-dimethyl-2-propenyl, 3-methyl-3-butenyl, allyl, p-methoxybenzyldiphenylmethyl, tetrahydrofuranyl, methoxymethyl, methylthiomethyl, benzyloxymethyl, 2,2,2-trichloroethoxymethyl, 2-(trimethylsilyl)ethoxymethyl, methylsulfonyl, p-toluenesulfonyl, C 1-8 Alkyl, C 1-8 Alkyl C(=O)-, C 1-8 Alkylsilyl, phenyl C 1-3 Alkyl, HOC(=O)(CH2) j C(=O)-, MC(=O)(CH2) jC(=O)-, triphenylmethyl, MMTr, DMTr, 4',4',4'-trimethoxytrityl, Among them, j, M, X, R x 、R y 、R c and R d has the meanings described in the present invention.

[0058] In some embodiments of the compounds described herein, Z and Y 1 and each is independently H, deuterium, benzyloxycarbonyl, 4-nitrobenzyloxycarbonyl, 4-bromobenzyloxycarbonyl, 4-methoxybenzyloxycarbonyl, biphenylmethoxycarbonyl, 2,2,2-trichloroethoxycarbonyl, 2-(trimethylsilyl)ethoxycarbonyl, allyloxycarbonyl, chloroacetyl, trifluoroacetyl, methoxyacetyl, phenoxyacetyl, benzoyl, 2,2,2-trichloroethyl, 2-trimethylsilylethyl, 1,1-dimethyl-2-propenyl, 3-methyl-3-butenyl, allyl, p-methoxybenzyldiphenylmethyl, tetrahydrofuranyl, methoxymethyl, methylthiomethyl, benzyloxymethyl, 2,2,2-trichloroethoxymethyl, 2-(trimethylsilyl)ethoxymethyl, methylsulfonyl, p-toluenesulfonyl, C 1-6 Alkyl, C 1-6 Alkyl C(=O)-, C 1-6 Alkylsilyl, benzyl, phenethyl, HOC(=O)(CH2) j C(=O)-, MC(=O)(CH2) j C(=O)-, triphenylmethyl, MMTr, DMTr, 4',4',4'-trimethoxytrityl, Among them, j, M, X, R x 、R y 、R c and R d has the meanings described in the present invention.

[0059] In some embodiments of the compounds described herein, X is Cl or Br.

[0060] In some embodiments of the compounds described herein, each R x and R y is independently a hydroxy protecting group.

[0061] In some embodiments of the compounds described herein, each R c and R d are independently H or an amino protecting group; or R c 、R dTogether with the nitrogen atom to which they are attached, they form a heterocyclic group consisting of 5-6 ring atoms, and the heterocyclic group consisting of 5-6 ring atoms is independently optionally substituted by 1, 2, 3 or 4 substituents selected from deuterium, hydroxyl, cyano, F, Cl, Br, I, methyl, ethyl, propyl, methoxy, ethoxy, 1-propoxy and 2-propoxy.

[0062] In some embodiments of the compounds described herein, R 2 9-fluorenylmethoxycarbonyl, benzyloxycarbonyl, 4-nitrobenzyloxycarbonyl, 4-bromobenzyloxycarbonyl, 4-methoxybenzyloxycarbonyl, biphenylmethoxycarbonyl, 2,2,2-trichloroethoxycarbonyl, 2-(trimethylsilyl)ethoxycarbonyl, allyloxycarbonyl, chloroacetyl, trifluoroacetyl, methoxyacetyl, phenoxyacetyl, benzoyl, methyl, tert-butyl, 2-trimethylsilylethyl, 1,1-dimethyl-2-propenyl, 3-methyl-3-butenyl, allyl, benzyl, p-methoxybenzyldiphenylmethyl, trityl, tetrahydrofuranyl, methoxymethyl, methylthiomethyl, benzyloxymethyl, 2,2,2-trichloroethoxymethyl, 2-(trimethylsilyl)ethoxymethyl, methylsulfonyl, p-toluenesulfonyl, trimethylsilyl, triethylsilyl, triisopropylsilyl, C 1-6 Alkoxy or R 3 C(=O)-, where R 3 has the meanings described in the present invention.

[0063] In some embodiments of the compounds described herein, each R a and R b are independently H, methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, tert-butyl, methoxy, ethoxy, 1-propoxy, 2-propoxy, 9-fluorenylmethoxycarbonyl, benzyloxycarbonyl, 4-nitrobenzyloxycarbonyl, 4-bromobenzyloxycarbonyl, 4-methoxybenzyloxycarbonyl, biphenylmethoxycarbonyl, 2,2,2-trichloroethoxycarbonyl, 2-(trimethylsilyl)ethoxycarbonyl, allyloxycarbonyl, chloroacetyl, trifluoroacetyl, methoxyacetyl, Phenoxyacetyl, benzoyl, 2-trimethylsilylethyl, 1,1-dimethyl-2-propenyl, 3-methyl-3-butenyl, allyl, benzyl, p-methoxybenzyldiphenylmethyl, trityl, tetrahydrofuranyl, methoxymethyl, methylthiomethyl, benzyloxymethyl, 2,2,2-trichloroethoxymethyl, 2-(trimethylsilyl)ethoxymethyl, methanesulfonyl, p-toluenesulfonyl, trimethylsilyl, triethylsilyl, triisopropylsilyl or R 4 C(=O)-, or R a 、R bTogether with the N atom to which they are attached, they form a pyrrolidinyl, morpholinyl, piperidinyl or piperazinyl group, wherein the pyrrolidinyl, morpholinyl, piperidinyl and piperazinyl groups are each independently optionally substituted with 1, 2, 3 or 4 substituents selected from deuterium, hydroxyl, cyano, F, Cl, Br, I, methoxy, ethoxy, 1-propoxy and 2-propoxy groups, wherein R 4 has the meanings described in the present invention.

[0064] In some embodiments of the compounds described herein, each R 3 and R 4 Independently C 1-6 Alkyl, halogenated C 1-6 Alkyl, C 1-6 Alkoxy, phenyl, halogen-substituted phenyl, C 1-6 Alkylphenyl or benzyl.

[0065] In some embodiments of the compounds described herein, each R 3 and R 4 Independently C 1-4 Alkyl, halogenated C 1-4 Alkyl, C 1-4 Alkoxy, phenyl, halogen-substituted phenyl, C 1-4 Alkylphenyl or benzyl.

[0066] In some embodiments of the compounds described herein, each R 3 and R 4 are independently methyl, ethyl, n-propyl, isopropyl, trifluoromethyl, difluoromethyl, monofluoromethyl, trichloromethyl, dichloromethyl, monochloromethyl, 2,2,2-trichloroethyl, methoxy, ethoxy, 1-propoxy, 2-propoxy, 1-butoxy, 2-methyl-1-propoxy, 2-butoxy, tert-butoxy, phenyl, halogen-substituted phenyl, C 1-3 Alkylphenyl or benzyl.

[0067] In some embodiments of the compounds described herein, each R x and R yare independently benzyloxycarbonyl, 4-nitrobenzyloxycarbonyl, 4-bromobenzyloxycarbonyl, 4-methoxybenzyloxycarbonyl, biphenylmethoxycarbonyl, 2,2,2-trichloroethoxycarbonyl, 2-(trimethylsilyl)ethoxycarbonyl, allyloxycarbonyl, chloroacetyl, trifluoroacetyl, methoxyacetyl, phenoxyacetyl, benzoyl, 2,2,2-trichloroethyl, 2-trimethylsilylethyl, 1,1-dimethyl-2-propenyl, 3-methyl-3-butenyl, allyl, p-methoxybenzyldiphenylmethyl, tetrahydrofuranyl, methoxymethyl, methylthiomethyl, benzyloxymethyl, 2,2,2-trichloroethoxymethyl, 2-(trimethylsilyl)ethoxymethyl, methylsulfonyl, p-toluenesulfonyl, cyano C 1-6 Alkyl, C 1-6 Alkyl, C 1-6 Alkyl C(=O)-, C 1-6 alkylsilyl, phenyl, halogen-substituted phenyl, benzyl or phenethyl.

[0068] In some embodiments of the compounds described herein, each R x and R y are independently benzyloxycarbonyl, 4-nitrobenzyloxycarbonyl, 4-bromobenzyloxycarbonyl, 4-methoxybenzyloxycarbonyl, biphenylmethoxycarbonyl, 2,2,2-trichloroethoxycarbonyl, 2-(trimethylsilyl)ethoxycarbonyl, allyloxycarbonyl, chloroacetyl, trifluoroacetyl, methoxyacetyl, phenoxyacetyl, benzoyl, 2,2,2-trichloroethyl, 2-trimethylsilylethyl, 1,1-dimethyl-2-propenyl, 3-methyl-3-butenyl, allyl , p-methoxybenzyldiphenylmethyl, tetrahydrofuranyl, methoxymethyl, methylthiomethyl, benzyloxymethyl, 2,2,2-trichloroethoxymethyl, 2-(trimethylsilyl)ethoxymethyl, methylsulfonyl, p-toluenesulfonyl, CNCH2-, CN(CH2)2-, CNCH(CH3)2CH2-, CN(CH2)3-, CNCH(CH3)2CH2CH2-, methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, tert-butyl, C 1-4 Alkyl C(=O)-, C 1-4 alkylsilyl, phenyl, halogen-substituted phenyl, benzyl or phenethyl.

[0069] In some embodiments of the compounds described herein, each R c and R dare independently methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, tert-butyl, methoxy, ethoxy, 1-propoxy, 2-propoxy, 9-fluorenylmethoxycarbonyl, benzyloxycarbonyl, 4-nitrobenzyloxycarbonyl, 4-bromobenzyloxycarbonyl, 4-methoxybenzyloxycarbonyl, biphenylmethoxycarbonyl, 2,2,2-trichloroethoxycarbonyl, 2-(trimethylsilyl)ethoxycarbonyl, allyloxycarbonyl, chloroacetyl, trifluoroacetyl, methoxyacetyl, phenoxy Acetyl, benzoyl, 2-trimethylsilylethyl, 1,1-dimethyl-2-propenyl, 3-methyl-3-butenyl, allyl, benzyl, p-methoxybenzyldiphenylmethyl, trityl, tetrahydrofuranyl, methoxymethyl, methylthiomethyl, benzyloxymethyl, 2,2,2-trichloroethoxymethyl, 2-(trimethylsilyl)ethoxymethyl, methanesulfonyl, p-toluenesulfonyl, trimethylsilyl, triethylsilyl, triisopropylsilyl, or R 4 C(=O)-, or R c 、R d Together with the N atom to which they are attached, they form a pyrrolidinyl, morpholinyl, piperidinyl or piperazinyl group, each of which is independently optionally substituted with 1, 2, 3 or 4 substituents selected from deuterium, hydroxyl, cyano, F, Cl, Br, I, methoxy, ethoxy, 1-propoxy and 2-propoxy.

[0070] In some embodiments of the compounds of the present invention, the compounds of the present invention have a structure as shown in formula (II),

[0071] In another aspect, the present invention also relates to a pharmaceutical composition comprising the double-stranded siRNA, its conjugate or salt thereof according to the present invention, and a pharmaceutically acceptable carrier.

[0072] In another aspect of the present invention, the present invention also relates to the use of the double-stranded siRNA conjugate, its conjugate and the pharmaceutical composition of the present invention in the preparation of drugs for treating and / or preventing hepatitis B disease.

[0073] In another aspect of the present invention, the present invention also relates to the use of the nucleotide residues of the present invention in drug research, gene function research and / or screening of a whole gene library for siRNA, wherein the structure of the nucleotide residues is:

[0074] In some embodiments of the application of the nucleotide residues described in the present invention, the siRNA drug is the double-stranded siRNA drug described in the present invention.

[0075] In another aspect of the present invention, the present invention also relates to the use of the compounds described in the present invention as raw materials for solid-phase synthesis of DNA nucleotides, raw materials for synthesis of oligonucleotide drugs, raw materials for synthesis of siRNA drugs, siRNA drug research, gene function research and / or screening of whole gene libraries.

[0076] In yet another aspect of the present invention, the present invention further relates to the use of the nucleotide residues of the present invention as oligonucleotide intercalating groups, wherein the oligonucleotide is a nucleotide sequence containing 10 to 50 nucleotides or nucleotide base pairs, and the oligonucleotide is capable of inhibiting or blocking gene expression, and the structure of the nucleotide residue is:

[0077] In some embodiments of the present invention in which the nucleotide residues are used as oligonucleotide intercalating groups, the gene is the HBV gene.

[0078] In some embodiments of the present invention, the nucleotide residues are used as oligonucleotide intercalating groups, wherein the oligonucleotide is siRNA.

[0079] In some embodiments of the present invention wherein the nucleotide residues are used as oligonucleotide intercalating groups, the siRNA comprises a sense strand and an antisense strand.

[0080] In some embodiments of the present invention, the nucleotide residue is used as an intercalating group in an oligonucleotide, wherein the nucleotide residue is only intercalated into the sense strand of the siRNA.

[0081] In some embodiments of the present invention, the nucleotide residue is used as an oligonucleotide intercalating group, wherein the nucleotide residue is only intercalated into the antisense strand of the siRNA.

[0082] In some embodiments of the present invention, the nucleotide residues are used as oligonucleotide intercalating groups, wherein the nucleotide residues are intercalated into the sense strand and the antisense strand of the siRNA.

[0083] In some embodiments of the present invention wherein the nucleotide residues are used as oligonucleotide intercalating groups, the sense strand of the siRNA comprises the sequence shown in SEQ ID NO: 19.

[0084] In some embodiments of the present invention wherein the nucleotide residues are used as oligonucleotide intercalating groups, the antisense strand of the siRNA comprises a sequence as shown in SEQ ID NO: 36 or SEQ ID NO: 33.

[0085] Detailed description of the present invention

[0086] Definitions and General Terms

[0087] In the present invention, the term "comprise" or "include" is an open expression, that is, it includes the content specified in the present invention, but does not exclude other aspects of the content.

[0088] In the present invention, the term "small interfering RNA (siRNA)" refers to a class of double-stranded RNA molecules with a length of 17 to 30 nucleotides, comprising a sense strand and an antisense strand. siRNA mediates the targeted cleavage of RNA transcripts in the RISC pathway by forming an RNA-induced silencing complex (RISC). Specifically, siRNA guides the specific degradation of mRNA sequences through the known RNA interference (RNAi) process, inhibiting the translation of mRNA into amino acids and proteins. For example, siRNA can regulate (e.g., inhibit) the expression of hepatitis B virus in cells.

[0089] In the present invention, the term "antisense strand (or guide strand)" refers to an siRNA strand that includes a region that is substantially complementary to a target sequence (e.g., a sequence in hepatitis B virus mRNA). The term "sense strand (or follower strand)" refers to an siRNA strand that includes a region that is substantially complementary to the antisense strand. The antisense strand or the sense strand in the double-stranded siRNA of the present invention contains one or more (e.g., 2, 3, 4, or 5) nucleotide residues Y, wherein Y has the structure described in the present invention.

[0090] The term "substantially complementary" refers to complete complementarity or at least partial complementarity, for example, the antisense strand is completely complementary or at least partially complementary to the target sequence. In the case of partial complementarity, mismatches can exist within the interior or terminal regions of the molecule, wherein the most tolerated mismatches exist within the terminal regions, for example, within 5, 4, 3 or 2 nucleotides of the 5'- and / or 3'-end of either strand of the siRNA.

[0091] It should be noted that "at least a portion of the antisense strand is substantially complementary to an mRNA" means that the antisense strand comprises a polynucleotide that is substantially complementary to a continuous portion of an mRNA of interest (e.g., an mRNA encoding hepatitis B virus). Alternatively, if a polynucleotide is substantially non-interruptedly complementary to a portion of an mRNA encoding hepatitis B virus, then the antisense strand is complementary to at least a portion of the hepatitis B virus mRNA.

[0092] In the present invention, the term "target sequence" refers to a continuous portion of the nucleotide sequence of an mRNA molecule formed during transcription of a gene encoding hepatitis B virus, including mRNA that is an RNA processing product of a primary transcription product.

[0093] In the present disclosure, a double-stranded siRNA analog refers to a complex of ribonucleic acid molecules having a double-stranded structure comprising two antiparallel and substantially complementary nucleic acid strands having "sense" and "antisense" orientations relative to the target RNA. In the present disclosure, "complementary" has the meaning known to those skilled in the art, i.e., in a double-stranded nucleic acid molecule, the bases of one strand are paired with the bases on the other strand in a complementary manner. The purine base adenine (A) is always paired with the pyrimidine base uracil (U); the purine base guanine (G) is always paired with the pyrimidine base cytosine (C). Each base pair includes a purine and a pyrimidine. When adenine on one strand is always paired with uracil on the other strand, and guanine is always paired with cytosine, the two strands are considered to be complementary to each other, and the sequence of the strand can be inferred from the sequence of its complementary strand.

[0094] In the present invention, the term "inhibiting the expression of hepatitis B virus genes" includes any level of inhibition of hepatitis B virus (HBV) genes, for example, at least partial inhibition of HBV gene expression, such as inhibition of at least about 20%, at least about 25%, at least about 30%, at least about 35%, at least about 40%, at least about 45%, at least about 50%, at least about 55%, at least about 60%, at least about 65%, at least about 70%, at least about 75%, at least about 80%, at least about 85%, at least about 90%, at least about 91%, at least about 92%, at least about 93%, at least about 94%, at least about 95%, at least about 96%, at least about 97%, at least about 98% or at least about 99%. The expression of HBV genes can be evaluated based on the level of any variable related to HBV gene expression, for example, HBV mRNA level or HBV protein level. Inhibition can be evaluated by the reduction of the absolute or relative level of one or more of these variables compared to a control level. A control level can be any type of control level utilized in the art, for example, a baseline level before administration, or a level determined from similar subjects, cells or samples that have never been treated or that have been treated with a control (e.g., a control or an inactive agent control using only a buffer).

[0095] In the present invention, "pharmaceutical composition" can refer to a composition used for treating a disease or for in vitro cell culture experiments. When used for treating a disease, the term "pharmaceutical composition" generally refers to a unit dosage form and can be prepared by any method well known in the pharmaceutical art. All methods include the step of combining the active ingredient with an excipient that constitutes one or more auxiliary ingredients. Typically, the composition is prepared by uniformly and thoroughly combining active double-stranded siRNA with a liquid excipient, a finely divided solid excipient, or both.

[0096] The siRNA of the present invention comprises a nucleotide group as a basic structural unit. It is well known to those skilled in the art that the nucleotide group comprises a phosphate group, a ribose group, and a base, which will not be described in detail here. Each nucleotide in the siRNA is independently a modified or unmodified nucleotide, preferably an unmodified nucleotide. The double-stranded siRNA of the present invention comprises a sense strand and an antisense strand.

[0097] The term "intercalation" used in the present invention means that an intercalating group is linked to at least one nucleotide residue in the sequence, including replacing a nucleotide residue in the sequence with an intercalating group (such as Y).

[0098] The "intercalating groups" described herein are residues of analogs of natural nucleotide bases, distinct from any patented natural nucleotide bases. When introduced into a nucleic acid sequence, these groups can impart certain functions (e.g., unexpected activity). For example, Y, as an intercalating group, can be incorporated into an oligonucleotide sequence to inhibit gene expression, thereby generating unexpected activity.

[0099] The "oligonucleotide intercalating group" of the present invention refers to the intercalating group connected to at least one nucleotide residue in the oligonucleotide, including replacing a nucleotide residue in the oligonucleotide with an intercalating group (such as Y).

[0100] The Y-embedded sequence of the present invention refers to a sequence in which at least one nucleotide residue is linked to a Y, including sequences in which a nucleotide residue is replaced by a Y. The Y-embedded sequence of the present invention may also be optionally modified, such as by methoxy modification, fluorination, and phosphorothioate linkage. The Y-embedded sequence of the present invention includes, but is not limited to, a Y-embedded siRNA, a Y-embedded sense strand, and a Y-embedded antisense strand.

[0101] The conjugate groups described herein include pharmaceutically acceptable conjugate groups. Generally, pharmaceutically acceptable conjugate groups include a pharmaceutically acceptable targeting molecule and an optional linker. Exemplary conjugate groups, linkers, and targeting molecule types can be found in WO2015006740A2 and CN114555188A. Exemplary conjugate groups include, but are not limited to, L96, NAG37, or DAW40007-4 described herein.

[0102] Unless otherwise indicated, "conjugation" refers to the covalent linkage of two or more chemical moieties, each with a specific function, to each other; accordingly, "conjugate" refers to a compound formed by covalent linkage of the chemical moieties.

[0103] The double-stranded siRNA conjugate of the present invention is a compound formed by connecting the double-stranded siRNA and a pharmaceutically acceptable conjugated group, and the double-stranded siRNA and the pharmaceutically acceptable conjugated group are covalently linked.

[0104] In the present invention, the term "pharmaceutically acceptable" means that the substance or composition must be chemically and / or toxicologically compatible with the other ingredients of the formulation and / or the mammal to be treated therewith. Preferably, the "pharmaceutically acceptable" herein means approved by federal regulatory agencies or national governments or listed in the United States Pharmacopoeia or other generally recognized pharmacopeia for use in animals, particularly humans.

[0105] In the present invention, the term "pharmaceutically acceptable excipient" may include any solvent, solid excipient, diluent, or other liquid excipient, etc., suitable for the specific target dosage form. Except to the extent that any conventional excipient is incompatible with the double-stranded siRNA, its conjugate, or its salt of the present invention, such as by producing any adverse biological effects or interacting in a deleterious manner with any other component of the pharmaceutically acceptable composition, their use is also contemplated by the present invention.

[0106] As used herein, the term "treatment" refers to any agent used to obtain a desired pharmacological and / or physiological effect. The effect may be preventive in terms of completely or partially preventing a disease or its symptoms, and / or therapeutic in terms of partially or completely curing a disease and / or the adverse effects caused by the disease. "Treatment" as used herein covers diseases in mammals, particularly humans, and includes: (a) preventing the occurrence of a disease or condition in an individual who is susceptible to the disease but has not yet been diagnosed with the disease; (b) inhibiting the disease, such as arresting the progression of the disease; or (c) alleviating the disease, such as alleviating the symptoms associated with the disease. "Treatment" as used herein covers any medication that administers a drug, RNAi agent or siRNA to an individual to treat, cure, alleviate, improve, reduce or inhibit the individual's disease, including but not limited to administering a drug containing an RNAi agent, siRNA or siRNA conjugate described herein to an individual in need.

[0107] Unless otherwise specified, in the context of the present invention, capital letters C, G, U, and A represent the base composition of natural nucleotides; lowercase letters c, g, u, and a respectively represent that the 2-position of the ribose on the nucleotide represented by the corresponding capital letter is modified by a methoxy group; an underline ___ below a capital letter represents that the 2-position of the ribose on the nucleotide represented by the letter is modified by a fluorine group; a spacer "●" represents that the two nucleotide residues adjacent to the spacer "●" are separated by a phosphorothioate group. If there is no "●" between nucleotide residues, it means that the nucleotide residues are linked by phosphate groups. For example, "g●u" indicates that the g and u residues are linked by a thiophosphate group, "gu" indicates that the g and u residues are linked by a phosphate group; Agn is adenosine-glycol nucleic acid (Glycol nucleic acid, GNA, ); Y in double-stranded siRNA represents The fluorine modification of the ribose position 2 in the present invention means that the hydroxyl group at the ribose position 2 is replaced by F; the methoxy modification of the ribose position 2 means that the hydroxyl group at the ribose position 2 is replaced by a methoxy group.

[0108] In the context of the present invention, Bz represents benzoyl; MMTr represents 4'-methoxytrityl; DMTr represents 4',4'-dimethoxytriphenylmethyl.

[0109] In the present invention, "phosphate group," "phosphate group," and "phosphate bond" are used interchangeably and include monophosphate, diester, or phosphotriester groups. The "phosphate group" in "phosphorothioate group" also has the same meaning. Unless otherwise specified, a natural internucleotide phosphate group is a phosphodiester group. Unless otherwise specified, a sequence in which Y replaces one or more nucleotide residues as described herein means that one Y replaces one nucleotide residue, not one Y replaces two or more nucleotide residues. If two nucleotide residues are replaced, then two Ys replace two nucleotide residues, respectively. For example, if the antisense strand comprises a sequence in which Y replaces 0, 1, 2, 3, 4, or 5 nucleotide residues in the sequence set forth in SEQ ID NO:40, then it should be understood that the antisense strand comprises a sequence in which 0, 1, 2, 3, 4, or 5 nucleotide residues in the sequence set forth in SEQ ID NO:40 are replaced by Y, respectively.

[0110] The term "oxo" refers to a =0 group, for example, a carbon atom and an oxygen atom connected by a double bond, wherein a ketone or an aldehyde is formed.

[0111] As used herein, "chemically modified" or "modification" means a structure that is chemically different when compared to a naturally occurring counterpart, including all changes by chemical means, such as the addition or removal of a chemical moiety, or the substitution of one chemical moiety for another.

[0112] The compounds of the present invention may be asymmetric, for example, having one or more stereoisomers. Unless otherwise indicated, all stereoisomers are included, such as enantiomers and diastereomers. Compounds of the present invention containing asymmetric carbon atoms can be isolated in optically pure or racemic forms. Optically pure forms can be resolved from racemic mixtures or synthesized by using chiral starting materials or chiral reagents.

[0113] Optically active (R)- and (S)-isomers, as well as D and L isomers, can be prepared by chiral synthesis or chiral reagents or other conventional techniques. If one enantiomer of a compound of the invention is desired, it can be prepared by asymmetric synthesis or derivatization with a chiral auxiliary, wherein the resulting diastereomeric mixture is separated and the auxiliary group is cleaved to provide the pure desired enantiomer. Alternatively, when the molecule contains a basic functional group (such as an amino group) or an acidic functional group (such as a carboxyl group), diastereomeric salts are formed with an appropriate optically active acid or base, followed by diastereomeric resolution by conventional methods known in the art, and then the pure enantiomers are recovered. In addition, separation of enantiomers and diastereomers is typically accomplished by using chromatography using a chiral stationary phase, optionally combined with chemical derivatization (e.g., carbamate formation from an amine).

[0114] The present invention also includes isotopically labeled compounds of the invention which are identical to those described herein, but in which one or more atoms are replaced by an atom having an atomic mass or mass number different from the atomic mass or mass number usually found in nature. Examples of isotopes that can be incorporated into the compounds of the invention include isotopes of hydrogen, carbon, nitrogen, oxygen, phosphorus, sulfur, fluorine, iodine, and chlorine, such as 2 H. 3 H. 11 C, 13C, 14 C. 13 N. 15 N. 15 O. 17 O. 18 O. 31 P. 32 P. 35 S. 18 F. 123 I. 125 I and 36 Cl et al.

[0115] Unless otherwise stated, when a position is particularly designated as deuterium (D), the position should be understood to have at least 1000 times the abundance of deuterium greater than the natural abundance of deuterium (which is 0.015%) (i.e., at least 10% deuterium incorporation). In the example, the compound has at least 1000 times the abundance of deuterium, at least 2000 times the abundance of deuterium, at least 3000 times the abundance of deuterium, at least 4000 times the abundance of deuterium, at least 5000 times the abundance of deuterium, at least 6000 times the abundance of deuterium or more abundant deuterium. The present invention also includes various deuterated forms of formula (I) compounds. Each available hydrogen atom connected to a carbon atom can be independently replaced by a deuterium atom. Those skilled in the art can synthesize deuterated forms of formula (I) compounds with reference to relevant literature. In preparing deuterated forms of compounds of formula (I), commercially available deuterated starting materials may be used, or they may be synthesized using conventional techniques using deuterated reagents, including but not limited to deuterated borane, trideuterated borane in tetrahydrofuran, deuterated lithium aluminum hydride, deuterated iodoethane, deuterated iodomethane, and the like.

[0116] The conjugated groups of the present invention can enhance the delivery of therapeutic agents to specific target locations (e.g., specific organs or tissues) within a subject such as a human or animal. In some embodiments of the present invention, the conjugated groups can enhance the targeted delivery of expression-inhibitory double-stranded siRNA. In some embodiments of the present invention, the conjugated groups can enhance the delivery of expression-inhibitory double-stranded siRNA to the liver.

[0117] The conjugated groups of the present invention can be directly or indirectly connected to a compound, such as a therapeutic agent, for example, an expression inhibitory oligonucleotide, for example, the 3' or 5' end of an expression inhibitory oligonucleotide. In some embodiments of the present invention, the expression inhibitory oligonucleotide comprises one or more modified nucleotides. In some embodiments of the present invention, the expression inhibitory oligonucleotide is an RNAi agent, such as a double-stranded siRNA agent comprising a sense strand and an antisense strand. In some embodiments of the present invention, the conjugated groups disclosed in the present invention are connected to the 3' end of the sense strand of the double-stranded siRNA agent. In some embodiments, the conjugated groups disclosed in the present invention are connected to the expression inhibitory oligonucleotide agent at the 3' end of the sense strand of the double-stranded siRNA agent via a phosphate, phosphorothioate or phosphonate group.

[0118] The definitions and conventions of stereochemistry used herein are generally those of S.P. Parker, Ed., McGraw-Hill Dictionary of Chemical Terms (1984) McGraw-Hill Book Company, New York; and Eliel, E. and Wilen, S., "Stereochemistry of Organic Compounds", John Wiley & Sons, Inc., New York, 1994. The compounds of the present invention may contain asymmetric centers or chiral centers and therefore exist as different stereoisomers. All stereoisomeric forms of the compounds of the present invention, including but not limited to diastereomers, enantiomers, atropisomers, and mixtures thereof, such as racemic mixtures, form part of the present invention. Many organic compounds exist in optically active forms, i.e., they have the ability to rotate the plane of plane-polarized light. When describing an optically active compound, the prefix D, L or R, S is used to indicate the absolute configuration of the molecule about its chiral center. The prefixes d, l, or (+), (-) are used to designate the sign of rotation of plane-polarized light in a compound. (-) or l means the compound is levorotatory, and the prefix (+) or d means the compound is dextrorotatory. These stereoisomers have the same chemical structure, but their stereostructures are different. Specific stereoisomers can be enantiomers, and a mixture of isomers is often called an enantiomeric mixture. A 50:50 mixture of enantiomers is called a racemic mixture or racemate, which may result in a lack of stereoselectivity or stereospecificity during chemical reactions. The terms "racemic mixture" and "racemate" refer to an equimolar mixture of two enantiomers that lacks optical activity.

[0119] The term "tautomer" or "tautomeric form" refers to structural isomers of different energies that are interconvertible via a low energy barrier. For example, proton tautomers (i.e., prototropic tautomers) include interconversions via proton migration, such as keto-enol and imine-enamine isomerizations.

[0120] The term "composition" refers to a mixture of one or more compounds described herein, or their physiologically acceptable salts or precursors, with other chemical components, as well as other components such as physiologically acceptable carriers and excipients. The purpose of a composition is to facilitate administration to an organism, facilitating absorption of the active ingredient and thereby exerting its biological activity.

[0121] The term "pharmaceutically acceptable excipient" or "pharmaceutically acceptable excipient" includes, but is not limited to, any adjuvant, carrier, excipient, glidant, sweetener, diluent, preservative, dye / colorant, flavoring agent, surfactant, wetting agent, dispersant, suspending agent, stabilizer, isotonic agent, solvent or emulsifier that has been approved by the U.S. Food and Drug Administration as acceptable for use in humans or domestic animals.

[0122] Unless otherwise specified, the "compound," "ligand," "nucleic acid conjugate," "double-stranded siRNA conjugate," "double-stranded siRNA," and "nucleic acid" of the present invention may independently exist in the form of a salt, a mixed salt, or a non-salt form (e.g., a free acid or a free base). When present in the form of a salt or a mixed salt, it may be a pharmaceutically acceptable salt.

[0123] The term "acceptable salt" includes acceptable acid addition salts and pharmaceutically acceptable base addition salts. "Acceptable acid addition salts" refers to salts formed with inorganic or organic acids that retain the biological effectiveness of the free base without other side effects. Inorganic acid salts include, but are not limited to, hydrochlorides, hydrobromides, sulfates, nitrates, and phosphates; organic acid salts include, but are not limited to, formates, acetates, 2,2-dichloroacetates, trifluoroacetates, propionates, caproates, octanoates, decanoates, undecylenates, glycolates, gluconates, lactates, sebacates, adipates, glutarates, malonates, oxalates, maleates, succinates, fumarates, tartrates, citrates, palmitates, stearates, oleates, cinnamates, laurates, malates, glutamate, pyroglutamate, aspartate, benzoates, methanesulfonates, benzenesulfonates, p-toluenesulfonates, alginate, ascorbate, salicylates, 4-aminosalicylates, and naphthalene disulfonates. These salts can be prepared by methods known in the art.

[0124] "Pharmaceutically acceptable base addition salts" refer to salts formed with inorganic or organic bases that retain the biological effectiveness of the free acid without other side effects. Salts derived from inorganic bases include, but are not limited to, sodium salts, potassium salts, lithium salts, ammonium salts, calcium salts, magnesium salts, iron salts, zinc salts, copper salts, manganese salts, aluminum salts, and the like. Preferred inorganic salts are ammonium salts, sodium salts, potassium salts, calcium salts, and magnesium salts, with sodium salts being preferred. Salts derived from organic bases include, but are not limited to, following salts: primary amines, secondary amines and tertiary amines, substituted amines, including natural substituted amines, cyclic amines and basic ion exchange resins, such as ammonia, isopropylamine, trimethylamine, diethylamine, triethylamine, tripropylamine, ethanolamine, diethanolamine, triethanolamine, dimethylethanolamine, 2-dimethylaminoethanol, 2-diethylaminoethanol, dicyclohexylamine, lysine, arginine, histidine, caffeine, procaine, choline, betaine, ethylenediamine, glucosamine, methylglucamine, theobromine, purine, piperazine, piperidine, N-ethylpiperidine, polyamine resins, etc. Preferred organic bases include isopropylamine, diethylamine, ethanolamine, trimethylamine, dicyclohexylamine, choline and caffeine. These salts can be prepared by methods known in the art.

[0125] As described herein, the compounds of the present invention may optionally be substituted with one or more substituents, as described above for the general formula compounds, or as described in the specific examples, subclasses, and classes of compounds encompassed by the present invention. Generally, the term "substituted" refers to the replacement of one or more hydrogen atoms in a given structure with a specified substituent. Unless otherwise indicated, an optionally substituted group may have a substituent at each substitutable position of the group. When more than one position in a given formula can be substituted with one or more substituents selected from a specified group, the substituents may be the same or different at each position.

[0126] In addition, it should be noted that, unless otherwise explicitly stated, the descriptions used throughout this document, “each ... and ... are independently,” “... and ... are each independently,” and “... and ... are respectively independently,” are interchangeable and should be understood in a broad sense. They may mean that in different groups, the specific options expressed by the same symbols do not affect each other, or that in the same group, the specific options expressed by the same symbols do not affect each other.

[0127] In the present invention, the terms "optionally", "optional" or "optionally" generally mean that the subsequently described event or circumstance can but need not occur, and that the description includes instances where the event or circumstance occurs and instances where it does not occur.

[0128] In various parts of this specification, substituents of compounds disclosed herein are disclosed in terms of group types or ranges. It is specifically noted that the present invention includes every independent subcombination of the individual members of these group types and ranges. For example, the term "C 1-6 "Alkyl" specifically refers to methyl, ethyl, C3 alkyl, C4 alkyl, C5 alkyl and C6 alkyl as disclosed independently.

[0129] The term "alkyl" as used herein includes saturated linear or branched monovalent hydrocarbon groups of 1 to 20 carbon atoms, wherein the alkyl group may be independently and optionally substituted with one or more substituents described herein. In some embodiments, the alkyl group contains 1 to 12 carbon atoms, in other embodiments, the alkyl group contains 1 to 10 carbon atoms, in other embodiments, the alkyl group contains 1 to 8 carbon atoms, in other embodiments, the alkyl group contains 1 to 6 carbon atoms, in other embodiments, the alkyl group contains 1 to 4 carbon atoms, and in other embodiments, the alkyl group contains 1 to 3 carbon atoms. Further examples of alkyl groups include, but are not limited to, methyl (Me, -CH3), ethyl (Et, -CH2CH3), n-propyl (n-Pr, -CH2CH2CH3), isopropyl (i-Pr, -CH(CH3)2), n-butyl (n-Bu, -CH2CH2CH2CH3), 2-methylpropyl or isobutyl (i-Bu, -CH2CH(CH3)2), 1-methylpropyl or sec-butyl (s-Bu, -CH(CH3)CH2CH3), tert-butyl (t-Bu, -CH(CH3)CH2CH3), 1-methylpropyl or sec-butyl (s ... -C(CH3)3), n-pentyl (-CH2CH2CH2CH2CH3), 2-pentyl (-CH(CH3)CH2CH2CH3), 3-pentyl (-CH(CH2CH3)2), 2-methyl-2-butyl (-C(CH3)2CH2CH3), 3-methyl-2-butyl (-CH(CH3)CH(CH3)2), 3-methyl-1-butyl (-CH2CH2CH(CH3)2), 2-methyl-1-butyl (-CH2CH(CH3)CH2CH3), n-hexyl (-CH2CH2CH2CH2CH2CH3), 2-hexyl (-CH(CH3)CH2CH2CH2CH3), 3-hexyl (-CH(CH2 3-Methyl-2-pentyl (-C(CH3)2CH2CH2CH3), 4-methyl-2-pentyl (-CH(CH3)CH2CH(CH3)2), 3-methyl-3-pentyl (-C(CH3)(CH2CH3)2), 2-methyl-3-pentyl (-CH(CH2CH3)CH(CH3)2), 2,3-dimethyl-2-butyl (-C(CH3)2CH(CH3)2), 3,3-dimethyl-2-butyl (-CH(CH3)C(CH3)3), n-heptyl, n-octyl, n-nonyl, n-heptyl, and the like.

[0130] The term "alkoxy" refers to an alkyl group attached to the remainder of a molecule through an oxygen atom, wherein the alkyl group has the meaning as described herein. Unless otherwise specified, the alkoxy group contains 1-12 carbon atoms. In some embodiments, the alkoxy group contains 1-8 carbon atoms; in other embodiments, the alkoxy group contains 1-6 carbon atoms; in other embodiments, the alkoxy group contains 1-4 carbon atoms; and in yet other embodiments, the alkoxy group contains 1-3 carbon atoms. The alkoxy group may be optionally substituted with one or more substituents as described herein.

[0131] Examples of alkoxy groups include, but are not limited to, methoxy (MeO, -OCH3), ethoxy (EtO, -OCH2CH3), 1-propoxy (n-PrO, n-propoxy, -OCH2CH2CH3), 2-propoxy (i-PrO, i-propoxy, -OCH(CH3)2), 1-butoxy (n-BuO, n-butoxy, -OCH2CH2CH2CH3), 2-methyl-1-propoxy (i-BuO, i-butoxy, -OCH2CH(CH3)2), 2-butoxy (s-BuO, s-butoxy, -OCH(CH3)CH2CH3), 2-methyl-2- Propoxy (t-BuO, t-butoxy, -OC(CH3)3), 1-pentyloxy (n-pentyloxy, -OCH2CH2CH2CH2CH3), 2-pentyloxy (-OCH(CH3)CH2CH2CH3), 3-pentyloxy (-OCH(CH2CH3)2), 2-methyl-2-butoxy (-OC(CH3)2CH2CH3), 3-methyl-2-butoxy (-OCH(CH3)CH(CH3)2), 3-methyl-l-butoxy (-OCH2CH2CH(CH3)2), 2-methyl-l-butoxy (-OCH2CH(CH3)CH2CH3) and the like.

[0132] The term "alkenyl" refers to a linear or branched monovalent, divalent or polyvalent hydrocarbon radical containing 2 to 12 carbon atoms, or 2 to 8 carbon atoms, or 2 to 6 carbon atoms, or 2 to 4 carbon atoms, wherein at least one position of CC is sp 2 Double bond, wherein the alkenyl group can be independently unsubstituted or substituted with one or more substituents described in the present invention, including "cis", "trans" or "Z", "E" isomers, specific examples of which include, but are not limited to, vinyl (-CH=CH2), propenyl (-CH=CHCH3), allyl (-CH2CH=CH2) and the like, wherein the alkenyl group can be independently unsubstituted or substituted with one or more substituents described in the present invention.

[0133] The term "consisting of M-M1 ring atoms" means that the cyclic group is composed of M-M1 ring atoms, wherein the ring atoms include carbon atoms and / or heteroatoms such as O, N, S, and P. For example, "a heterocyclic group consisting of 3-6 ring atoms" means a monoheterocyclic group consisting of 3, 4, 5, or 6 ring atoms.

[0134] The term "heterocyclyl" refers to a non-aromatic, saturated or partially unsaturated monocyclic, bicyclic or tricyclic ring system containing 3-12 ring atoms, wherein at least one ring atom is selected from nitrogen, sulfur or oxygen atoms. The heterocyclyl group may be optionally substituted with one or more substituents described herein. Unless otherwise specified, the heterocyclyl group may be carbonyl or nitrogenyl, and the -CH2- group may be optionally replaced by -C(=O)- or -C(=S)-. The sulfur atom of the ring may be optionally oxidized to an S-oxide. The nitrogen atom of the ring may be optionally oxidized to an N-oxide. In some embodiments, the heterocyclyl group is a heterocyclyl group consisting of 3-12 ring atoms, in some embodiments, the heterocyclyl group is a heterocyclyl group consisting of 5-10 ring atoms, in some embodiments, the heterocyclyl group is a heterocyclyl group consisting of 3-6 ring atoms, in some embodiments, the heterocyclyl group is a heterocyclyl group consisting of 4-6 ring atoms, in some embodiments, the heterocyclyl group is a heterocyclyl group consisting of 5-6 ring atoms, in other embodiments, the heterocyclyl group is a heterocyclyl group consisting of 4 atoms, which refers to a monovalent or polyvalent, saturated or partially unsaturated, non-aromatic monocyclic ring containing 4 ring atoms, wherein at least one ring atom is selected from nitrogen, sulfur and oxygen atoms. In other embodiments, the heterocyclyl group is a heterocyclyl group consisting of 5 atoms, which refers to a monovalent or polyvalent, saturated or partially unsaturated, non-aromatic monocyclic ring containing 5 ring atoms, wherein at least one ring atom is selected from nitrogen, sulfur and oxygen atoms. In other embodiments, the heterocyclic group is a 6-atom heterocyclic group, which refers to a monovalent or polyvalent, saturated or partially unsaturated, non-aromatic monocyclic ring containing 6 ring atoms, wherein at least one ring atom is selected from nitrogen, sulfur and oxygen atoms. "Heterocyclic group" also includes groups formed by condensing a heterocyclic group with a saturated or partially unsaturated ring or heterocyclic ring. Examples of heterocyclic rings include, but are not limited to, pyrrolidinyl, tetrahydrofuranyl, dihydrofuranyl, tetrahydrothiophenyl, tetrahydropyranyl, dihydropyranyl, tetrahydrothiopyranyl, piperidinyl, morpholinyl, thiomorpholinyl, thioxanyl, piperazinyl, homopiperazinyl, azetidinyl, oxetanyl, thietanyl, homopiperidinyl, glycidyl, azepanyl, oxetanyl, thiepanyl, oxazepinyl, diazepinyl, thiazepinyl, 2-pyrrolinyl, 3- pyrrolinyl, indolinyl, 2H-pyranyl, 4H-pyranyl, dioxanyl, 1,3-dioxolane, pyrazolinyl, dithianyl, dithiolanyl, dihydrothienyl, pyrazolidinylimidazolinyl, imidazolidinyl, 1,2,3,4-tetrahydroisoquinolinyl, 3-azabicyclo[3.1.0]hexyl, 3-azabicyclo[4.1.0]heptyl, azabicyclo[2.2.2]hexyl, 3H-indolylquinolizinyl and N-pyridylurea.Examples of heterocyclic groups also include 1,1-dioxothiomorpholinyl, examples of which the carbon atoms on the ring are replaced by oxo (=O) include, but are not limited to, pyrimidinedione, 1,2,4-thiadiazole-5(4H)-one, 1,2,4-oxadiazole-5(4H)-one, 1H-1,2,4-triazole-5(4H)-one, etc., examples of which the carbon atoms on the ring are replaced by a group =S include, but are not limited to, 1,2,4-oxadiazole-5(4H)-thione, 1,3,4-oxadiazole-2(3H)-thione, etc.

[0135] The term "heteroatom" refers to one or more O, S, N, P and Si, including N, S and P in any oxidation state; in the form of primary, secondary, tertiary amines and quaternary ammonium salts; or in the form of a nitrogen atom in a heterocyclic ring in which the hydrogen is substituted, for example, N (such as N in 3,4-dihydro-2H-pyrrolyl), NH (such as NH in pyrrolidinyl) or NR (such as NR in N-substituted pyrrolidinyl, wherein R represents a substituent as described herein).

[0136] The terms "alkylsilyl" and "alkylsilyl" refer to silyl (-SiH3) groups in which the hydrogen atoms are independently replaced by 1, 2, or 3 alkyl groups. In some embodiments, the alkylsilyl group is 1, 2, or 3 C 1-12 In other embodiments, the alkylsilyl group is 1, 2 or 3 C 1-9 In other embodiments, the alkylsilyl group is 1, 2 or 3 C 1-6 In other embodiments, the alkylsilyl group is 1, 2 or 3 C 1-4 Alkyl groups are lower alkylsilyl groups formed by connecting an alkyl group to a silicon atom. In still other embodiments, an alkylsilyl group is 1, 2 or 3 C 1-3 An alkyl group is a lower alkylsilyl group formed by connecting an alkyl group to a silicon atom. Suitable alkylsilyl groups can be monoalkylsilyl, dialkylsilyl or trialkylsilyl. Examples of alkylsilyl groups include, but are not limited to, trimethylsilyl (-Si(CH3)3), triethylsilyl (-Si(CH2CH3)3), tri-n-propylsilyl (-Si(CH2CH2CH3)3), and the like.

[0137] The term "hydroxy protecting group" refers to an unstable chemical moiety that protects the hydroxyl group from undesirable reactions during one or more synthesis procedures. After the one or more synthesis procedures, the hydroxy protecting group can be selectively removed. Hydroxy protecting groups as known in the art are generally described in TH Greene and PGM Wuts, Protective Groups in Organic Synthesis, 3rd edition, John Wiley & Sons, New York (1999). Examples of hydroxy protecting groups of the present invention include, but are not limited to, C 1-12 alkyl, benzyloxycarbonyl, 4-nitrobenzyloxycarbonyl, 4-bromobenzyloxycarbonyl, 4-methoxybenzyloxycarbonyl, methoxycarbonyl, tert-butoxycarbonyl, isopropyloxycarbonyl, biphenylmethoxycarbonyl, 2,2,2-trichloroethoxycarbonyl, 2-(trimethylsilyl)ethoxycarbonyl, 2-furfuryloxycarbonyl, allyloxycarbonyl, acetyl (Ac or -C(O)CH3), formyl, chloroacetyl, trifluoroacetyl, methoxyacetyl, phenoxyacetyl, benzoyl (Bz or -C(O)C6H5), C 1-10 Alkyl (methyl, tert-butyl, etc.), 2,2,2-trichloroethyl, 2-trimethylsilylethyl, 1,1-dimethyl-2-propenyl, 3-methyl-3-butenyl, allyl, C 6-10 Aryl C 1-4 Alkyl (such as benzyl, phenethyl, etc.), p-methoxybenzyldiphenylmethyl, triphenylmethyl (triphenylmethyl or trityl), tetrahydrofuranyl, methoxymethyl, methylthiomethyl, benzyloxymethyl, 2,2,2-trichloroethoxymethyl, 2-(trimethylsilyl)ethoxymethyl, methanesulfonyl, p-toluenesulfonyl, C 1-10 Alkylsilyl (such as trimethylsilyl (TMS or -Si(CH3)3)), triethylsilyl, triisopropylsilyl, MMTr, DMTr or 4',4',4'-trimethoxytrityl, etc.

[0138] The term "amino protecting group" refers to an unstable chemical moiety that protects the amino group from undesirable reaction during the building-up sequence. After the one or more building-up sequences, the amino protecting group as described herein can be selectively removed. Amino protecting groups as known in the art are generally described in TH Greene and PGM Woods, Protective Groups in Organic Synthesis, the 3rd edition, John Wiley & Sons, New York (1999). The example of amino protecting groups includes but is not limited to acetyl, tert-butyloxycarbonyl, 9-fluorenylmethoxycarbonyl and benzyloxycarbonyl etc.

[0139] Term " solid phase support " specifically represents any particle, pearl or the surface on which oligonucleotide synthesis can occur.For example inorganic solid phase support and organic solid phase support, all can be selected for use in embodiments of the present invention.Inorganic solid phase support is preferably selected from silica gel and controlled pore glass beads (Controlled-pore glass is called for short CPG).Organic solid phase support is a resin, preferably macroporous resin, more preferably highly cross-linked polystyrene, Tentagel (graft copolymer made up of low cross-linked polystyrene matrix, polyethylene glycol (PEG or POE) is grafted thereon), polyvinyl acetate (PVA), copolymer, aminopolyethylene glycol and cellulose etc. of Bo Luosi (Poros)-polystyrene / divinylbenzene.Preferred embodiments of the present invention utilize solid phase support based on CPG.Many other purchasable solid phase supports all belong to the present invention. Description of the drawings:

[0140] Figure 1 shows the inhibitory effects of the present invention compound DAW30227 (i.e., double-stranded siRNA conjugate S146), the control compound DAW30025 (i.e., double-stranded siRNA conjugate S149), and a vehicle control group (normal saline) on HBsAg in an HBV-Tg mouse model. SD in the figure represents single dose.

[0141] Figure 2 shows the inhibitory effects of the present invention compound DAW30335 (i.e., double-stranded siRNA conjugate S147), the control compound DAW30025 (i.e., double-stranded siRNA conjugate S149), DAW30336 (i.e., siRNA conjugate S151) and the vehicle control group (normal saline) on HBsAg in the AAV mouse model experiment.

[0142] Detailed description of the compounds of the present invention

[0143] The present invention provides a novel targeting compound that can be used to prepare a nucleic acid drug for targeted delivery of oligonucleotides to the liver. The present invention also provides a nucleotide conjugate, a method for its preparation, and its use, which exhibits high in vivo delivery efficiency, good stability, high gene expression inhibition activity in hepatocytes, and / or low toxicity. In yet another aspect, the present invention further provides an siRNA reagent, a method for its preparation, and its use, which exhibits high in vivo delivery efficiency, good stability, high gene expression inhibition activity in HBV, and / or low toxicity.

[0144] The present invention aims to provide a novel double-stranded siRNA, its conjugates, its salts, and their uses, and specifically relates to the use of the double-stranded siRNA and its conjugates of the present invention in the preparation of a medicament for treating and / or preventing hepatitis B. Furthermore, the present invention relates to a novel compound and its use as a raw material for solid-phase synthesis of DNA nucleotides, a raw material for the synthesis of siRNA drugs, siRNA drug research, gene function research, and / or screening of whole gene libraries, particularly as a raw material for the synthesis of the double-stranded siRNA drugs of the present invention. Furthermore, the present invention relates to a novel nucleotide residue and its use in siRNA drug research, gene function research, and / or screening of whole gene libraries, as well as its use as an intercalating group in oligonucleotides. The double-stranded siRNA and its conjugates of the present invention have high gene expression inhibitory activity and / or low toxicity against HBV.

[0145] In one aspect, the present invention relates to a double-stranded siRNA, a conjugate thereof, or a salt thereof, wherein the double-stranded siRNA comprises a sense strand and an antisense strand, wherein the double-stranded siRNA comprises one or more Ys (i.e., the double-stranded siRNA of the present invention comprises at least one Y), and the Y is Unless otherwise specified, each nucleotide and Y in the double-stranded siRNA of the present invention are independently modified or unmodified. Optionally, the Y can be at any position in the double-stranded siRNA.

[0146] In some embodiments of the double-stranded siRNA, its conjugate or salt thereof of the present invention, the double-stranded siRNA comprises 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10 Ys.

[0147] In some embodiments of the double-stranded siRNA, its conjugate or salt thereof of the present invention, the double-stranded siRNA comprises 1, 2, 3, 4 or 5 Y. Optionally, the Y can be at any position in the double-stranded siRNA.

[0148] In some embodiments of the double-stranded siRNA, its conjugate or salt thereof of the present invention, the sense strand in the double-stranded siRNA comprises at least one (e.g., 1, 2, 3, 4 or 5) Y. Optionally, the Y can be at any position in the sense strand.

[0149] In some embodiments of the double-stranded siRNA, its conjugate or salt thereof of the present invention, the antisense strand in the double-stranded siRNA comprises at least one (e.g., 1, 2, 3, 4 or 5) Y. Optionally, the Y can be at any position in the antisense strand.

[0150] In some embodiments of the double-stranded siRNA, its conjugate, or salt thereof of the present invention, in the double-stranded siRNA, the sense strand comprises 0 or at least one (e.g., 1, 2, 3, 4, or 5) Y, and the antisense strand comprises at least one (e.g., 1, 2, 3, 4, or 5) Y. Optionally, the Y may be at any position on the sense strand or the antisense strand.

[0151] In some embodiments of the double-stranded siRNA, conjugates, or salts thereof according to the present invention, the antisense strand of the double-stranded siRNA according to the present invention is no longer than 30 nucleotides. Preferably, the antisense strand of the double-stranded siRNA according to the present invention is no longer than 23 nucleotides. More preferably, the antisense strand of the double-stranded siRNA according to the present invention is no longer than 21 nucleotides.

[0152] In some embodiments of the double-stranded siRNA of the present invention, its conjugate or salt, the length of the sense strand of the double-stranded siRNA of the present invention does not exceed 30 nucleotides. Preferably, the length of the sense strand of the double-stranded siRNA of the present invention does not exceed 23 nucleotides. More preferably, the length of the sense strand of the double-stranded siRNA of the present invention does not exceed 19 or 21 nucleotides.

[0153] In some embodiments of the double-stranded siRNA, its conjugate, or its salt of the present invention, the antisense strand comprises a sequence as shown in 5'-UGUGAAGCGAAGUGCACACUU-3' (SEQ ID NO: 40), or a sequence in which one or more (e.g., 1, 2, 3, 4, or 5) nucleotide residues are replaced with Y in the sequence as shown in SEQ ID NO: 40; wherein each nucleotide and Y in the antisense strand are independently modified or unmodified, and the length of the antisense strand does not exceed 23 nucleotides. Optionally, the Y replacement occurs at any position in the sequence as shown in SEQ ID NO: 40,

[0154] In some embodiments of the double-stranded siRNA, its conjugate, or salt thereof of the present invention, the sense strand comprises a sequence as shown in 5'-GUGUGCACUUCGCUUCACA-3' (SEQ ID NO: 20), or a sequence in which one or more (e.g., 1, 2, 3, 4, or 5) nucleotide residues are replaced with Y in the sequence as shown in SEQ ID NO: 20; wherein, each nucleotide and Y in the sense strand are independently modified or unmodified, and the length of the sense strand does not exceed 23 nucleotides. Optionally, the Y replacement occurs at any position in the sequence as shown in SEQ ID NO: 20.

[0155] In some embodiments of the double-stranded siRNA, its conjugate or salt thereof of the present invention, the antisense strand comprises a sequence in which one or more (e.g., 1, 2, 3, 4 or 5) nucleotide residues are substituted with Y in the sequence as shown in 5'-UGUGAAGCGAAGUGCACACUU-3' (SEQ ID NO: 40); the sense strand comprises a sequence in which one or more (e.g., 1, 2, 3, 4 or 5) nucleotide residues are substituted with Y in the sequence as shown in SEQ ID NO: 20; wherein the Y substitution occurs at any position in the sequence as shown in SEQ ID NO: 40 or SEQ ID NO: 20, and the length of the antisense strand and the sense strand are each independently no more than 23 nucleotides.

[0156] In some embodiments of the double-stranded siRNA, its conjugate or salt thereof of the present invention, 70%, 75%, 80%, 85%, 90% or more of the nucleotides and Y in the sense strand or antisense strand of the double-stranded siRNA are modified.

[0157] In some embodiments of the double-stranded siRNA, its conjugate or salt thereof of the present invention, 70%, 75%, 80%, 85%, 90% or more of the nucleotides and Y in the sense strand and the antisense strand of the double-stranded siRNA are modified.

[0158] In some embodiments of the double-stranded siRNA, its conjugate or salt thereof of the present invention, each nucleotide and Y in the double-stranded siRNA is modified.

[0159] In some embodiments of the double-stranded siRNA, its conjugate or its salt of the present invention, the modification is selected from at least one of the following: 2'-methoxy modification (i.e., the hydroxyl group at position 2 of ribose is replaced by a methoxy group), 2'-methoxyethyl modification (i.e., the hydroxyl group at position 2 of ribose is replaced by a methoxyethyl group), 2'-fluoro modification (i.e., the hydroxyl group at position 2 of ribose is replaced by an F group), thiophosphate linkage, 2'-deoxy modification, 2'-amino modification (i.e., the hydroxyl group at position 2 of ribose is replaced by an amino group), locked nucleic acid modification, unlocked nucleic acid modification, ethylene glycol nucleic acid modification and 5'-vinyl phosphate modification.

[0160] In some embodiments of the double-stranded siRNA, its conjugate or salt thereof of the present invention, the sense strand comprises a sequence in which 0, 1, 2, 3, 4 or 5 nucleotide residues are replaced with Y in the sequence as shown in SEQ ID NO: 20, wherein each nucleotide and Y in the sense strand are independently modified or unmodified.

[0161] In some embodiments of the double-stranded siRNA, its conjugate, or a salt thereof of the present invention, the sense strand comprises a sequence in which one nucleotide residue is replaced by Y in the sequence shown in SEQ ID NO: 20.

[0162] In some embodiments of the double-stranded siRNA, its conjugate or salt thereof of the present invention, the antisense strand comprises a sequence in which 0, 1, 2, 3, 4 or 5 nucleotide residues are replaced by Y in the sequence as shown in SEQ ID NO: 40, wherein each nucleotide and Y of the antisense strand are independently modified or unmodified.

[0163] In some embodiments of the double-stranded siRNA, its conjugate, or a salt thereof of the present invention, the antisense strand comprises a sequence in which one nucleotide residue is replaced by Y in the sequence shown in SEQ ID NO: 40.

[0164] In some embodiments of the double-stranded siRNA, its conjugate or salt thereof of the present invention, the Y substitution occurs at positions 1 to 19 of the 5' end of the sequence as shown in SEQ ID NO: 20 (i.e., the Y substitution optionally occurs at position 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18 or 19 of the 5' end of the sequence as shown in SEQ ID NO: 20).

[0165] In some embodiments of the double-stranded siRNA, its conjugate or salt thereof of the present invention, the Y substitution occurs at position 1 to 21 of the 5' end of the sequence as shown in SEQ ID NO: 40 (i.e., the Y substitution optionally occurs at position 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20 or 21 of the 5' end of the sequence as shown in SEQ ID NO: 40).

[0166] In some embodiments of the double-stranded siRNA, its conjugate or salt thereof of the present invention, the sense strand comprises a sequence in which 0, 1, 2, 3, 4 or 5 nucleotide residues are replaced with Y in the sequence as shown in 5'-g●u●guGcACUucgcuucaca-3' (SEQ ID NO: 19), wherein each nucleotide and Y of the sense strand are independently modified or unmodified, and the Y replacement occurs at positions 1 to 19 at the 5' end of SEQ ID NO: 19 (i.e., the Y replacement optionally occurs at position 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18 or 19 at the 5' end of the sequence as shown in SEQ ID NO: 19), and the length of the sense strand does not exceed 23 nucleotides.

[0167] In some embodiments of the double-stranded siRNA, its conjugate or salt of the present invention, the antisense strand comprises a sequence in which 0, 1, 2, 3, 4 or 5 nucleotide residues are replaced with Y in the sequence as shown in 5'-u●G●ugaAgCGaaguGcAcac●u●u-3' (SEQ ID NO: 36), wherein each nucleotide and Y of the antisense strand are independently modified or unmodified, and the Y replacement occurs at positions 1 to 21 of the 5' end of the antisense strand SEQ ID NO: 36 (i.e., the Y replacement optionally occurs at position 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18 or 19 of the 5' end of the sequence as shown in SEQ ID NO: 36), and the length of the antisense strand does not exceed 23 nucleotides.

[0168] In some embodiments of the double-stranded siRNA, its conjugate or salt thereof of the present invention, the antisense strand comprises a sequence in which 0, 1, 2, 3, 4 or 5 nucleotide residues are substituted with Y in the sequence as shown in 5'-u●G●uga(Agn)gCGaaguGcAcac●u●u-3' (SEQ ID NO: 33), wherein each nucleotide and Y of the antisense strand are independently modified or unmodified, and the Y substitution occurs at positions 1 to 21 at the 5' end of the sequence as shown in SEQ ID NO: 33 (i.e., the Y substitution optionally occurs at position 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18 or 19 at the 5' end of the sequence as shown in SEQ ID NO: 33)), and the length of the antisense strand does not exceed 23 nucleotides.

[0169] Unless otherwise specified, in the context of the present invention, the capital letters C, G, U, and A in oligonucleotides or siRNA represent the base composition of natural nucleotides; the lowercase letters c, g, u, and a respectively indicate that the 2-position of the ribose on the nucleotide represented by the corresponding capital letter is modified by a methoxy group; the underline ___ under the capital letter indicates that the 2-position of the ribose on the nucleotide represented by the letter is modified by a fluorine group; Agn is adenosine-ethylene glycol nucleic acid; the spacer "●" indicates that the two nucleotide residues adjacent to the spacer "●" are connected by a thiophosphate group.

[0170] In some embodiments of the double-stranded siRNA, its conjugate or salt of the present invention, the sense strand comprises one of the following nucleotide sequences:

[0171] SEQ ID NO:1, SEQ ID NO:2, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:6, SEQ ID NO:7, SEQ ID NO:8, SEQ ID NO:9, SEQ ID NO:10, SEQ ID NO:11, SEQ ID NO:12, SEQ ID NO:13, SEQ ID NO:14, SEQ ID NO:15, SEQ ID NO:16, SEQ ID NO:17, SEQ ID NO:18, SEQ ID NO:19 and SEQ ID NO:21;

[0172] The length of the sense strand does not exceed 23 nucleotides.

[0173] In some embodiments of the double-stranded siRNA, its conjugate or salt of the present invention, the antisense strand comprises one of the following nucleotide sequences:

[0174] :

[0175] SEQ ID NO:22, SEQ ID NO:23, SEQ ID NO:24, SEQ ID NO:25, SEQ ID NO:26, SEQ ID NO:27, SEQ ID NO:28, SEQ ID NO:29, SEQ ID NO:30, SEQ ID NO:31, SEQ ID NO:32, SEQ ID NO:33, SEQ ID NO:34, SEQ ID NO:35, SEQ ID NO:36, SEQ ID NO:37, SEQ ID NO:38 and SEQ ID NO:39;

[0176] The antisense strand is no more than 23 nucleotides in length.

[0177] In some embodiments of the double-stranded siRNA, its conjugate or salt of the present invention, the double-stranded siRNA comprises one of the following:

[0178] having a sense strand comprising the nucleotide sequence set forth in SEQ ID NO: 15 and an antisense strand comprising the nucleotide sequence set forth in SEQ ID NO: 25, wherein the length of the sense strand and the antisense strand each independently does not exceed 23 nucleotides;

[0179] having a sense strand comprising the nucleotide sequence set forth in SEQ ID NO: 17 and an antisense strand comprising the nucleotide sequence set forth in SEQ ID NO: 25, wherein the length of the sense strand and the antisense strand each independently does not exceed 23 nucleotides;

[0180] having a sense strand comprising the nucleotide sequence set forth in SEQ ID NO: 15 and an antisense strand comprising the nucleotide sequence set forth in SEQ ID NO: 26, wherein the length of the sense strand and the antisense strand each independently does not exceed 23 nucleotides;

[0181] having a sense strand comprising the nucleotide sequence set forth in SEQ ID NO: 16 and an antisense strand comprising the nucleotide sequence set forth in SEQ ID NO: 26, wherein the length of the sense strand and the antisense strand each independently does not exceed 23 nucleotides;

[0182] having a sense strand comprising the nucleotide sequence set forth in SEQ ID NO: 17 and an antisense strand comprising the nucleotide sequence set forth in SEQ ID NO: 26, wherein the length of the sense strand and the antisense strand each independently does not exceed 23 nucleotides;

[0183] having a sense strand comprising the nucleotide sequence set forth in SEQ ID NO: 15 and an antisense strand comprising the nucleotide sequence set forth in SEQ ID NO: 27, wherein the length of the sense strand and the antisense strand each independently does not exceed 23 nucleotides;

[0184] having a sense strand comprising the nucleotide sequence set forth in SEQ ID NO: 16 and an antisense strand comprising the nucleotide sequence set forth in SEQ ID NO: 27, wherein the length of the sense strand and the antisense strand each independently does not exceed 23 nucleotides;

[0185] having a sense strand comprising the nucleotide sequence set forth in SEQ ID NO: 17 and an antisense strand comprising the nucleotide sequence set forth in SEQ ID NO: 27, wherein the length of the sense strand and the antisense strand each independently does not exceed 23 nucleotides;

[0186] having a sense strand comprising the nucleotide sequence set forth in SEQ ID NO: 16 and an antisense strand comprising the nucleotide sequence set forth in SEQ ID NO: 28, wherein the length of the sense strand and the antisense strand each independently does not exceed 23 nucleotides;

[0187] having a sense strand comprising the nucleotide sequence shown in SEQ ID NO: 17 and an antisense strand comprising the nucleotide sequence shown in SEQ ID NO: 28, wherein the length of the sense strand and the antisense strand is each independently no more than 23 nucleotides; or

[0188] The sense strand has a nucleotide sequence shown in SEQ ID NO: 18, and the antisense strand has a nucleotide sequence shown in SEQ ID NO: 28, wherein the length of the sense strand and the antisense strand each independently does not exceed 23 nucleotides.

[0189] In some embodiments of the double-stranded siRNA, its conjugate, or a salt thereof of the present invention, the double-stranded siRNA is selected from one of S1 to S143 in Table 1. In other embodiments of the double-stranded siRNA, its conjugate, or a salt thereof of the present invention, the conjugate of the double-stranded siRNA is selected from S146, S147, and S150 in Table 1.

[0190] Table 1

[0191] The capital letters C, G, U, and A represent the base composition of natural nucleotides; the lowercase letters c, g, u, and a represent that the 2-position of the ribose sugar on the nucleotide represented by the corresponding capital letter is modified by a methoxy group; the underline ___ below the capital letter represents that the 2-position of the ribose sugar on the nucleotide represented by the letter is modified by a fluorine group; the spacer "●" indicates that the two nucleotide residues adjacent to the spacer "●" are connected by a phosphorothioate group; Agn is adenosine-glycol nucleic acid (GNA); Y in double-stranded siRNA represents

[0192] In some embodiments of the double-stranded siRNA, its conjugate, or salt thereof of the present invention, the double-stranded siRNA conjugate comprises the double-stranded siRNA and a conjugation group, that is, the double-stranded siRNA conjugate is a conjugate of the double-stranded siRNA conjugated to the conjugation group, wherein the conjugation group includes but is not limited to L-96 or DAW40007-4, and the structures of L-96 and DAW40007-4 are respectively:

[0193] In some embodiments of the double-stranded siRNA, its conjugate, or salt thereof of the present invention, the conjugated group is conjugated to the 3' end or the 5' end of the sense strand of the double-stranded siRNA.

[0194] In some embodiments of the double-stranded siRNA, its conjugate, or salt thereof of the present invention, the conjugated group is conjugated to the 3' end of the sense strand of the double-stranded siRNA.

[0195] In some embodiments of the double-stranded siRNA, its conjugate or salt thereof of the present invention, the double-stranded siRNA is linked to the conjugated group through a phosphate group, a phosphorothioate group or a phosphate group.

[0196] In some embodiments of the double-stranded siRNA, its conjugate or salt of the present invention, the 3' end or 5' end of the sense strand of the double-stranded siRNA is linked to the conjugated group through a phosphate group, a phosphorothioate group or a phosphate group.

[0197] On the other hand, the present invention also relates to a nucleotide residue Y having the structure:

[0198] On the other hand, the present invention also relates to a compound having a structure as shown in formula (I), or a stereoisomer, tautomer or acceptable salt of the compound as shown in formula (I),

[0199] Among them, each R, Z, Y 1 and R 1has the meaning as described in the present invention.

[0200] In some embodiments of the compounds described herein, R 1 is methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl or tert-butyl, each of which is independently optionally substituted with 1, 2, 3 or 4 substituents selected from deuterium, hydroxyl, cyano, F, Cl, Br, I, methoxy, ethoxy, 1-propoxy and 2-propoxy.

[0201] In some embodiments of the compounds described herein, Z and Y 1 are independently H, deuterium, a hydroxyl protecting group, HOC(=O)(CH2) j C(=O)-, MC(=O)(CH2) j C(═O)—, a phosphate group, a thiophosphate group, a phosphite amide group or a hydrogen phosphate group, wherein each j and M has the meanings described in the present invention.

[0202] As long as any Y that can enable the compound of the present invention to participate in oligonucleotide synthesis 1 The groups all belong to the present invention, such as active phosphate groups such as phosphate groups, thiophosphate groups, phosphite amide groups or hydrogen phosphate groups all belong to the content of the present invention, and they can be obtained by the compounds described in the present invention through the preparation methods disclosed in the art, such as the phosphodiester method, phosphotriester method and hydrogen phosphate method described in Section 3 of the master's thesis "Chemical Synthesis Research of Nucleic Acids and Synthesis and Interference Activity Test of 4'-C-Hydroxy Modified siRNA" to obtain the compounds of the present application, and for example, they can be prepared by the method described in the document Kyle W. Knouse et al. "Unlocking P (V): Reagents for chiral phosphorothioate synthesis" 2018. Pages 6-9.

[0203] The phosphates described in the present invention include phosphoric acid diesters and triesters; the thiophosphates described include phosphoric acid diesters and triesters; and the hydrogen phosphate group refers to the group formed by the salt formed by the phosphoric acid group and the base.

[0204] In some embodiments of the compounds described herein, M is a solid support, preferably a hydroxyl- or amino-functionalized solid support, more preferably a resin or CPG, further preferably a macroporous resin or CPG, and even more preferably an aminomethyl resin, a hydroxyl resin, or -NHCPG;

[0205] In some embodiments of the compounds described herein, R is -NHR 2 or -N=CH-NR aR b ; Among them. Each R 2 、R a and R b has the meaning as described in the present invention.

[0206] In some embodiments of the compounds described herein, R 2 is an amino protecting group.

[0207] In some embodiments of the compounds described herein, each R a and R b are independently H or an amino protecting group, or R a 、R b Together with the nitrogen atom to which they are attached, they form a heterocyclic group consisting of 5-6 ring atoms, and each heterocyclic group consisting of 5-6 ring atoms is independently optionally substituted by 1, 2, 3 or 4 substituents selected from deuterium, hydroxyl, cyano, F, Cl, Br, I, methyl, ethyl, n-propyl, isopropyl, methoxy, ethoxy, 1-propoxy and 2-propoxy.

[0208] In some embodiments of the compounds described herein, each j is independently 1, 2, 3, 4, or 5.

[0209] In some embodiments of the compounds described herein, Z and Y 1 and each is independently H, deuterium, benzyloxycarbonyl, 4-nitrobenzyloxycarbonyl, 4-bromobenzyloxycarbonyl, 4-methoxybenzyloxycarbonyl, biphenylmethoxycarbonyl, 2,2,2-trichloroethoxycarbonyl, 2-(trimethylsilyl)ethoxycarbonyl, allyloxycarbonyl, chloroacetyl, trifluoroacetyl, methoxyacetyl, phenoxyacetyl, benzoyl, 2,2,2-trichloroethyl, 2-trimethylsilylethyl, 1,1-dimethyl-2-propenyl, 3-methyl-3-butenyl, allyl, p-methoxybenzyldiphenylmethyl, tetrahydrofuranyl, methoxymethyl, methylthiomethyl, benzyloxymethyl, 2,2,2-trichloroethoxymethyl, 2-(trimethylsilyl)ethoxymethyl, methylsulfonyl, p-toluenesulfonyl, C 1-12 Alkyl, C 1-12 Alkyl C(=O)-, C 1-12 Alkylsilyl, C 6-10 Aryl C 1-6 Alkyl, HOC(=O)(CH2) j C(=O)-, MC(=O)(CH2) j C(=O)-, triphenylmethyl, MMTr, DMTr, 4',4',4'-trimethoxytrityl, Among them, j, M, X, R x 、R y 、Rc and R d has the meanings described in the present invention.

[0210] In some embodiments of the compounds described herein, Z and Y 1 and each independently represents H, deuterium, benzyloxycarbonyl, 4-nitrobenzyloxycarbonyl, 4-bromobenzyloxycarbonyl, 4-methoxybenzyloxycarbonyl, biphenylmethoxycarbonyl, 2,2,2-trichloroethoxycarbonyl, 2-(trimethylsilyl)ethoxycarbonyl, allyloxycarbonyl, chloroacetyl, trifluoroacetyl, methoxyacetyl, phenoxyacetyl, benzoyl, 2,2,2-trichloroethyl, 2-trimethylsilylethyl, 1,1-dimethyl-2-propenyl, 3-methyl-3-butenyl, allyl, p-methoxybenzyldiphenylmethyl, tetrahydrofuranyl, methoxymethyl, methylthiomethyl, benzyloxymethyl, 2,2,2-trichloroethoxymethyl, 2-(trimethylsilyl)ethoxymethyl, methylsulfonyl, p-toluenesulfonyl, C 1-10 Alkyl, C 1-10 Alkyl C(=O)-, C 1-10 Alkylsilyl, C 6-10 Aryl C 1-4 Alkyl, HOC(=O)(CH2) j C(=O)-, MC(=O)(CH2) j C(=O)-, triphenylmethyl, MMTr, DMTr, 4',4',4'-trimethoxytrityl, Among them, j, M, X, R x 、R y 、R c and R d has the meanings described in the present invention.

[0211] In some embodiments of the compounds described herein, Z and Y 1 and each is independently H, deuterium, benzyloxycarbonyl, 4-nitrobenzyloxycarbonyl, 4-bromobenzyloxycarbonyl, 4-methoxybenzyloxycarbonyl, biphenylmethoxycarbonyl, 2,2,2-trichloroethoxycarbonyl, 2-(trimethylsilyl)ethoxycarbonyl, allyloxycarbonyl, chloroacetyl, trifluoroacetyl, methoxyacetyl, phenoxyacetyl, benzoyl, 2,2,2-trichloroethyl, 2-trimethylsilylethyl, 1,1-dimethyl-2-propenyl, 3-methyl-3-butenyl, allyl, p-methoxybenzyldiphenylmethyl, tetrahydrofuranyl, methoxymethyl, methylthiomethyl, benzyloxymethyl, 2,2,2-trichloroethoxymethyl, 2-(trimethylsilyl)ethoxymethyl, methylsulfonyl, p-toluenesulfonyl, C 1-8 Alkyl, C 1-8 Alkyl C(=O)-, C 1-8Alkylsilyl, phenyl C 1-3 Alkyl, HOC(=O)(CH2) j C(=O)-, MC(=O)(CH2) j C(=O)-, triphenylmethyl, MMTr, DMTr, 4',4',4'-trimethoxytrityl, Among them, j, M, X, R x 、R y 、R c and R d has the meanings described in the present invention.

[0212] In some embodiments of the compounds described herein, Z and Y 1 and each is independently H, deuterium, benzyloxycarbonyl, 4-nitrobenzyloxycarbonyl, 4-bromobenzyloxycarbonyl, 4-methoxybenzyloxycarbonyl, biphenylmethoxycarbonyl, 2,2,2-trichloroethoxycarbonyl, 2-(trimethylsilyl)ethoxycarbonyl, allyloxycarbonyl, chloroacetyl, trifluoroacetyl, methoxyacetyl, phenoxyacetyl, benzoyl, 2,2,2-trichloroethyl, 2-trimethylsilylethyl, 1,1-dimethyl-2-propenyl, 3-methyl-3-butenyl, allyl, p-methoxybenzyldiphenylmethyl, tetrahydrofuranyl, methoxymethyl, methylthiomethyl, benzyloxymethyl, 2,2,2-trichloroethoxymethyl, 2-(trimethylsilyl)ethoxymethyl, methylsulfonyl, p-toluenesulfonyl, C 1-6 Alkyl, C 1-6 Alkyl C(=O)-, C 1-6 Alkylsilyl, benzyl, phenethyl, HOC(=O)(CH2) j C(=O)-, MC(=O)(CH2) j C(=O)-, triphenylmethyl, MMTr, DMTr, 4',4',4'-trimethoxytrityl, Among them, j, M, X, R x 、R y 、R c and R d has the meanings described in the present invention.

[0213] In some embodiments of the compounds described herein, X is Cl or Br.

[0214] In some embodiments of the compounds described herein, each R x and R y is independently a hydroxy protecting group.

[0215] In some embodiments of the compounds described herein, each R c and R dare independently H or an amino protecting group; or R c 、R d Together with the nitrogen atom to which they are attached, they form a heterocyclic group consisting of 5-6 ring atoms, and the heterocyclic group consisting of 5-6 ring atoms is independently optionally substituted by 1, 2, 3 or 4 substituents selected from deuterium, hydroxyl, cyano, F, Cl, Br, I, methyl, ethyl, propyl, methoxy, ethoxy, 1-propoxy and 2-propoxy.

[0216] In some embodiments of the compounds described herein, R 2 9-fluorenylmethoxycarbonyl, benzyloxycarbonyl, 4-nitrobenzyloxycarbonyl, 4-bromobenzyloxycarbonyl, 4-methoxybenzyloxycarbonyl, biphenylmethoxycarbonyl, 2,2,2-trichloroethoxycarbonyl, 2-(trimethylsilyl)ethoxycarbonyl, allyloxycarbonyl, chloroacetyl, trifluoroacetyl, methoxyacetyl, phenoxyacetyl, benzoyl, methyl, tert-butyl, 2-trimethylsilylethyl, 1,1-dimethyl-2-propenyl, 3-methyl-3-butenyl, allyl, benzyl, p-methoxybenzyldiphenylmethyl, trityl, tetrahydrofuranyl, methoxymethyl, methylthiomethyl, benzyloxymethyl, 2,2,2-trichloroethoxymethyl, 2-(trimethylsilyl)ethoxymethyl, methylsulfonyl, p-toluenesulfonyl, trimethylsilyl, triethylsilyl, triisopropylsilyl, C 1-6 Alkoxy or R 3 C(=O)-, where R 3 has the meanings described in the present invention.

[0217] In some embodiments of the compounds described herein, each R a and R b are independently H, methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, tert-butyl, methoxy, ethoxy, 1-propoxy, 2-propoxy, 9-fluorenylmethoxycarbonyl, benzyloxycarbonyl, 4-nitrobenzyloxycarbonyl, 4-bromobenzyloxycarbonyl, 4-methoxybenzyloxycarbonyl, biphenylmethoxycarbonyl, 2,2,2-trichloroethoxycarbonyl, 2-(trimethylsilyl)ethoxycarbonyl, allyloxycarbonyl, chloroacetyl, trifluoroacetyl, methoxyacetyl, Phenoxyacetyl, benzoyl, 2-trimethylsilylethyl, 1,1-dimethyl-2-propenyl, 3-methyl-3-butenyl, allyl, benzyl, p-methoxybenzyldiphenylmethyl, trityl, tetrahydrofuranyl, methoxymethyl, methylthiomethyl, benzyloxymethyl, 2,2,2-trichloroethoxymethyl, 2-(trimethylsilyl)ethoxymethyl, methanesulfonyl, p-toluenesulfonyl, trimethylsilyl, triethylsilyl, triisopropylsilyl or R 4 C(=O)-, or Ra 、R b Together with the N atom to which they are attached, they form pyrrolidinyl, morpholinyl, piperidinyl and piperazinyl, each of which is independently optionally substituted with 1, 2, 3 or 4 substituents selected from deuterium, hydroxyl, cyano, F, Cl, Br, I, methoxy, ethoxy, 1-propoxy and 2-propoxy, wherein R 4 has the meanings described in the present invention.

[0218] In some embodiments of the compounds described herein, each R 3 and R 4 Independently C 1-6 Alkyl, halogenated C 1-6 Alkyl, C 1-6 Alkoxy, phenyl, halogen-substituted phenyl, C 1-6 Alkylphenyl or benzyl.

[0219] In some embodiments of the compounds described herein, each R 3 and R 4 Independently C 1-4 Alkyl, halogenated C 1-4 Alkyl, C 1-4 Alkoxy, phenyl, halogen-substituted phenyl, C 1-4 Alkylphenyl or benzyl.

[0220] In some embodiments of the compounds described herein, each R 3 and R 4 are independently methyl, ethyl, n-propyl, isopropyl, trifluoromethyl, difluoromethyl, monofluoromethyl, trichloromethyl, dichloromethyl, monochloromethyl, 2,2,2-trichloroethyl, methoxy, ethoxy, 1-propoxy, 2-propoxy, 1-butoxy, 2-methyl-1-propoxy, 2-butoxy, tert-butoxy, phenyl, halogen-substituted phenyl, C 1-3 Alkylphenyl or benzyl.

[0221] In some embodiments of the compounds described herein, each R x and R yare independently benzyloxycarbonyl, 4-nitrobenzyloxycarbonyl, 4-bromobenzyloxycarbonyl, 4-methoxybenzyloxycarbonyl, biphenylmethoxycarbonyl, 2,2,2-trichloroethoxycarbonyl, 2-(trimethylsilyl)ethoxycarbonyl, allyloxycarbonyl, chloroacetyl, trifluoroacetyl, methoxyacetyl, phenoxyacetyl, benzoyl, 2,2,2-trichloroethyl, 2-trimethylsilylethyl, 1,1-dimethyl-2-propenyl, 3-methyl-3-butenyl, allyl, p-methoxybenzyldiphenylmethyl, tetrahydrofuranyl, methoxymethyl, methylthiomethyl, benzyloxymethyl, 2,2,2-trichloroethoxymethyl, 2-(trimethylsilyl)ethoxymethyl, methylsulfonyl, p-toluenesulfonyl, cyano C 1-6 Alkyl, C 1-6 Alkyl, C 1-6 Alkyl C(=O)-, C 1-6 alkylsilyl, phenyl, halogen-substituted phenyl, benzyl or phenethyl.

[0222] In some embodiments of the compounds described herein, each R x and R y are independently benzyloxycarbonyl, 4-nitrobenzyloxycarbonyl, 4-bromobenzyloxycarbonyl, 4-methoxybenzyloxycarbonyl, biphenylmethoxycarbonyl, 2,2,2-trichloroethoxycarbonyl, 2-(trimethylsilyl)ethoxycarbonyl, allyloxycarbonyl, chloroacetyl, trifluoroacetyl, methoxyacetyl, phenoxyacetyl, benzoyl, 2,2,2-trichloroethyl, 2-trimethylsilylethyl, 1,1-dimethyl-2-propenyl, 3-methyl-3-butenyl, allyl , p-methoxybenzyldiphenylmethyl, tetrahydrofuranyl, methoxymethyl, methylthiomethyl, benzyloxymethyl, 2,2,2-trichloroethoxymethyl, 2-(trimethylsilyl)ethoxymethyl, methylsulfonyl, p-toluenesulfonyl, CNCH2-, CN(CH2)2-, CNCH(CH3)2CH2-, CN(CH2)3-, CNCH(CH3)2CH2CH2-, methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, tert-butyl, C 1-4 Alkyl C(=O)-, C 1-4 alkylsilyl, phenyl, halogen-substituted phenyl, benzyl or phenethyl.

[0223] In some embodiments of the compounds described herein, each R c and R dare independently methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, tert-butyl, methoxy, ethoxy, 1-propoxy, 2-propoxy, 9-fluorenylmethoxycarbonyl, benzyloxycarbonyl, 4-nitrobenzyloxycarbonyl, 4-bromobenzyloxycarbonyl, 4-methoxybenzyloxycarbonyl, biphenylmethoxycarbonyl, 2,2,2-trichloroethoxycarbonyl, 2-(trimethylsilyl)ethoxycarbonyl, allyloxycarbonyl, chloroacetyl, trifluoroacetyl, methoxyacetyl, phenoxy Acetyl, benzoyl, 2-trimethylsilylethyl, 1,1-dimethyl-2-propenyl, 3-methyl-3-butenyl, allyl, benzyl, p-methoxybenzyldiphenylmethyl, trityl, tetrahydrofuranyl, methoxymethyl, methylthiomethyl, benzyloxymethyl, 2,2,2-trichloroethoxymethyl, 2-(trimethylsilyl)ethoxymethyl, methanesulfonyl, p-toluenesulfonyl, trimethylsilyl, triethylsilyl, triisopropylsilyl, or R 4 C(=O)-, or R c 、R d Together with the N atom to which it is attached, it forms a pyrrolidinyl, morpholinyl, piperidinyl or piperazinyl group, and the pyrrolidinyl, morpholinyl, piperidinyl and piperazinyl groups are independently optionally substituted with 1, 2, 3 or 4 substituents selected from deuterium, hydroxyl, cyano, F, Cl, Br, I, methoxy, ethoxy, 1-propoxy and 2-propoxy groups.

[0224] In some embodiments of the compounds of the present invention, the compounds of the present invention have a structure as shown in formula (II),

[0225] In another aspect, the present invention also relates to a pharmaceutical composition comprising the double-stranded siRNA, its conjugate or salt thereof according to the present invention, and a pharmaceutically acceptable carrier.

[0226] In another aspect of the present invention, the present invention also relates to the use of the siRNA conjugate, its conjugate and the pharmaceutical composition of the present invention in the preparation of drugs for treating and / or preventing hepatitis B disease.

[0227] In another aspect of the present invention, the present invention also relates to the use of the nucleotide residues of the present invention in drug research, gene function research and / or screening of a whole gene library for siRNA, wherein the structure of the nucleotide residues is:

[0228] In some embodiments of the application of the nucleotide residues described in the present invention, the siRNA drug is the double-stranded siRNA drug described in the present invention.

[0229] In another aspect of the present invention, the present invention also relates to the use of the compounds described in the present invention as raw materials for solid-phase synthesis of DNA nucleotides, raw materials for synthesis of oligonucleotide drugs, raw materials for synthesis of siRNA drugs, siRNA drug research, gene function research and / or screening of whole gene libraries.

[0230] In yet another aspect of the present invention, the present invention further relates to the use of the nucleotide residues of the present invention as oligonucleotide intercalating groups, wherein the oligonucleotide is a nucleotide sequence containing 10 to 50 nucleotides or nucleotide base pairs, and the oligonucleotide is capable of inhibiting or blocking gene expression, and the structure of the nucleotide residue is:

[0231] In some embodiments of the present invention in which the nucleotide residues are used as oligonucleotide intercalating groups, the gene is the HBV gene.

[0232] In some embodiments of the present invention, the nucleotide residues are used as oligonucleotide intercalating groups, wherein the oligonucleotide is siRNA.

[0233] In some embodiments of the present invention wherein the nucleotide residues are used as oligonucleotide intercalating groups, the siRNA comprises a sense strand and an antisense strand.

[0234] In some embodiments of the present invention, the nucleotide residue is used as an intercalating group in an oligonucleotide, wherein the nucleotide residue is only intercalated into the sense strand of the siRNA.

[0235] In some embodiments of the present invention, the nucleotide residue is used as an oligonucleotide intercalating group, wherein the nucleotide residue is only intercalated into the antisense strand of the siRNA.

[0236] In some embodiments of the present invention, the nucleotide residues are used as oligonucleotide intercalating groups, wherein the nucleotide residues are intercalated into the sense strand and the antisense strand of the siRNA.

[0237] In some embodiments of the present invention wherein the nucleotide residues are used as oligonucleotide intercalating groups, the sense strand of the siRNA comprises the sequence shown in SEQ ID NO: 19.

[0238] In some embodiments of the present invention wherein the nucleotide residues are used as oligonucleotide intercalating groups, the antisense strand of the siRNA comprises a sequence as shown in SEQ ID NO: 36 or SEQ ID NO: 33.

[0239] On the other hand, the present invention also provides a method for inhibiting the expression of a specific gene in liver cells in a patient, which comprises administering to the patient the double-stranded siRNA and double-stranded siRNA conjugate of the present invention or a composition thereof, wherein the nucleic acid ligand conjugate or the composition thereof may be a therapeutically effective amount.

[0240] In another aspect, the double-stranded siRNA conjugate, the conjugate and the salt thereof, or the pharmaceutical composition of the present invention is used for treating and / or preventing hepatitis B disease.

[0241] On the other hand, the compounds of the present invention are used as raw materials for solid-phase synthesis of DNA nucleotides, raw materials for synthesis of oligonucleotide drugs, raw materials for synthesis of siRNA drugs, siRNA drug research, gene function research and / or screening of whole gene libraries.

[0242] On the other hand, the nucleotide residue of the present invention is used as an oligonucleotide intercalating group, wherein the oligonucleotide is a nucleotide sequence containing 10 to 50 nucleotides or nucleotide base pairs, and the oligonucleotide can inhibit or block gene expression.

[0243] In some embodiments, the gene of the present invention is an HBV gene.

[0244] In some embodiments, the oligonucleotide is siRNA.

[0245] In some embodiments, the siRNA comprises a sense strand and an antisense strand.

[0246] In some embodiments, the nucleotide residues are incorporated only into the sense strand of the siRNA.

[0247] In some embodiments, the nucleotide residues are incorporated only into the antisense strand of the siRNA.

[0248] In some embodiments, the nucleotide residues are intercalated into both the sense and antisense strands of the siRNA.

[0249] In some embodiments, the sense strand of the siRNA comprises the sequence shown in SEQ ID NO: 19.

[0250] In some embodiments, the antisense strand of the siRNA comprises the sequence shown in SEQ ID NO:36 or SEQ ID NO:33.

[0251] In another aspect, the present invention relates to a method for treating and / or preventing hepatitis B, comprising using the double-stranded siRNA conjugate, its conjugate and salt thereof, or the pharmaceutical composition of the present invention.

[0252] On the other hand, the present invention relates to a method for solid-phase synthesis of DNA nucleotides, synthesis of oligonucleotide drugs, synthesis of siRNA drugs, siRNA drug research, gene function research and / or screening of a whole gene library, which method comprises using the compound described in the present invention.

[0253] In another aspect, the present invention relates to a method for inhibiting or blocking gene expression, comprising using a nucleotide sequence comprising 10 to 50 nucleotides or nucleotide base pairs, wherein the nucleotide sequence has the nucleotide residues of the present invention embedded therein.

[0254] In some embodiments, the gene is an HBV gene.

[0255] In some embodiments, the oligonucleotide is siRNA.

[0256] In some embodiments, the siRNA comprises a sense strand and an antisense strand.

[0257] In some embodiments, the nucleotide residues are incorporated only into the sense strand of the siRNA.

[0258] In some embodiments, the nucleotide residues are incorporated only into the antisense strand of the siRNA.

[0259] In some embodiments, the nucleotide residues are intercalated into both the sense and antisense strands of the siRNA.

[0260] In some embodiments, the sense strand of the siRNA comprises the sequence shown in SEQ ID NO: 19.

[0261] In some embodiments, the antisense strand of the siRNA comprises a sequence as shown in SEQ ID NO: 36 or SEQ ID NO: 33. Nucleic acid conjugates, preparations, administration and disease treatment methods of the present invention

[0262] The effective amount of the nucleic acid conjugate (such as siRNA conjugate or pharmaceutical composition) of the present invention may vary depending on the mode of administration and the severity of the disease to be treated. The selection of the preferred effective amount can be determined by a person of ordinary skill in the art based on various factors (e.g., through clinical trials). The factors include, but are not limited to: pharmacokinetic parameters of the active ingredient, such as bioavailability, metabolism, half-life, etc.; the severity of the disease to be treated, the patient's weight, the patient's immune status, the route of administration, etc. For example, depending on the urgency of the treatment condition, several divided doses may be administered daily, for example, at a dosage of four times a day, three times a day, twice a day, once a day, or every other day, or the administration of several doses per day may be proportionally reduced.

[0263] The drug can be administered to a subject by any suitable route known in the art, including but not limited to oral or parenteral routes, including intravenous administration, intramuscular administration, subcutaneous administration, transdermal administration, airway administration (aerosol), pulmonary administration, nasal administration, rectal administration and topical administration (including buccal administration and sublingual administration), preferably intravenous administration.

[0264] The pharmaceutical compositions disclosed herein include formulations suitable for parenteral administration. The formulations can conveniently be presented in unit dosage form and can be prepared by any method known in the pharmaceutical art. The amount of active ingredient that can be combined with excipients to prepare a single dose is generally the amount of siRNA that will produce a therapeutic effect. Generally, in percent units, this amount is from about 1% to about 99% of the active ingredient, preferably from about 5% to about 70%, and most preferably from about 10% to about 30%.

[0265] In another aspect of the present invention, the present invention provides a method for inhibiting the expression or activity of hepatitis B virus genes. According to an embodiment of the present invention, the method comprises: contacting the aforementioned siRNA, the aforementioned siRNA conjugate or the aforementioned pharmaceutical composition with cells. As mentioned above, the aforementioned siRNA and siRNA conjugate can both degrade the mRNA of hepatitis B virus and inhibit the expression and replication of HBV. Therefore, the method of the present invention can be used to inhibit the expression or activity of hepatitis B virus genes. For example, the expression or activity of hepatitis B virus genes can be inhibited in animals; or the expression or activity of hepatitis B virus genes can be inhibited for non-disease treatment purposes, such as inhibiting the expression or activity of hepatitis B virus genes in vitro for subsequent research.

[0266] In yet another aspect, the present invention provides a method for preventing and / or treating hepatitis B virus-induced diseases. According to an embodiment of the present invention, the method comprises administering a pharmaceutically acceptable amount of the aforementioned siRNA, siRNA conjugate, or pharmaceutical composition to a subject. According to an embodiment of the present invention, the method can effectively prevent and / or treat diseases associated with hepatitis B virus-induced diseases.

[0267] General synthesis methods of the compounds, double-stranded siRNA, and double-stranded siRNA conjugates of the present invention

[0268] Generally, the compounds and nucleic acid conjugates of the present invention can be prepared by the methods described herein, wherein, unless otherwise specified, the substituents are defined as shown in formulas (I) and (II). The following reaction schemes and examples are provided to further illustrate the present invention.

[0269] In the examples described below, all temperatures are in degrees Celsius (°C) unless otherwise indicated. Silica gel (200-300 mesh) was purchased from Qingdao Ocean Chemical Plant, and NH2CPG was purchased from Hebei Dinaxingke. Nuclear magnetic resonance spectra were obtained using CDC13, DMSO-d6, CD3OD, or acetone-d6 as solvents (in ppm), with TMS (0 ppm) or chloroform (7.25 ppm) as the reference standard. When multiple peaks are present, the following abbreviations are used: s (singlet), d (doublet), t (triplet), m (multiplet), br (broadened), dd (doublet of doublets), dt (doublet of triplets), br.s (broadened singlet), and q (quartet). Coupling constants, J, are expressed in Hertz (Hz).

[0270] Low-resolution mass spectrometry (MS) data were measured by an Agilent 6320 series LC-MS spectrometer equipped with a G1312A binary pump and a G1316A TCC (column temperature was maintained at 30 °C). A G1329A autosampler and a G1315B DAD detector were used for analysis, and an ESI source was applied to the LC-MS spectrometer.

[0271] High-resolution mass spectrometry (MS) data were determined by an Agilent 6130 series LC-MS spectrometer equipped with a G1311A quaternary pump and a G1316A TCC (column temperature maintained at 30 °C). A G1329A autosampler and a G1315D DAD detector were used for analysis, and an ESI source was applied to the HR-MS spectrometer.

[0272] The following abbreviations are used throughout the present invention: EDCI 1-ethyl-3(3-dimethylpropylamine)carbodiimide EDCI 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide HOBT 1-hydroxybenzotriazole EA ethyl acetate TFA trifluoroacetic acid HOBT 1-hydroxybenzotriazole Py pyridine DMAP 4-dimethylaminopyridine PE petroleum ether MsCl methanesulfonyl chloride ACN acetonitrile TMSOTf trimethylsilyl trifluoromethanesulfonate Ac2O acetic anhydride THF tetrahydrofuran Boc tert-butyloxycarbonyl mL milliliters MeOH methanol min minutes DMSO dimethyl sulfoxide M,N,mol / L moles / liter DMF N,N-dimethylformamide h hours DCM dichloromethane RT,rt room temperature DIPEA N,N-diisopropylethylamine HBTU benzotriazole-N,N,N',N'-tetramethyluronium hexafluorophosphate DETAILED DESCRIPTION

[0273] The scheme of the present invention will be explained below with reference to the examples. Those skilled in the art will understand that the following examples are only used to illustrate the present invention and should not be regarded as limiting the scope of the present invention. In particular, the synthesis of small nucleic acids and the synthesis of nucleic acid conjugates can be synthesized according to the embodiments of the present invention or routine adjustments in the art. If specific techniques or conditions are not specified in the examples, they are carried out according to the techniques or conditions described in the literature in the art or according to the product instructions. Reagents or instruments used without indicating the manufacturer are all conventional products that can be purchased commercially.

[0274] Synthesis method of the compound of the present invention

[0275] The following synthesis scheme lists the general experimental steps for preparing the compounds disclosed in the present invention, including those skilled in the art can make appropriate modifications to the method or adjustment of the raw materials according to actual conditions to prepare the compounds of the present invention. 1 and R have the meanings as described in the present invention; wherein, Z 1 is a hydroxyl protecting group, Y 2 MC(=O)(CH2) j C(=O)-, phosphate group, phosphorothioate group, phosphite amide group or hydrogen phosphate group, wherein M has the meaning as defined in the present invention. Unless otherwise specified, the compounds of the present invention can be prepared by the methods described in the following synthesis schemes.

[0276] Synthesis Scheme 1:

[0277] Compound (1-C) can be prepared by referring to the preparation method of Synthesis Scheme 1. First, compound (1-A) is protected with a hydroxyl protecting group to obtain compound (1-B). Compound (1-B) is then reacted with a suitable phosphate reagent or solid support to obtain compound (1-C) containing an active phosphate group or solid support. Stereoisomers of compound (1-C) can also be prepared by referring to the preparation method of Synthesis Scheme 1.

[0278] Preparation Example

[0279] In the following preparation examples, the inventors describe in detail the preparation process of the compounds of the present invention using some of the compounds of the present invention as examples, wherein: For CPG.

[0280] Example 1: Synthesis of Monomers

[0281] Step 1: Synthesis of compound 1-2

[0282] (2R,3R,5R)-2-(4-aminopyrrolo[2,1-f][1,2,4]triazin-7-yl)-3,4-dihydroxy-5-(hydroxymethyl)tetrahydrofuran-2-carbonitrile (i.e., compound 1-1) (1.0 g, 3.43 mmol) was added to pyridine (15 mL). The mixture was protected by nitrogen and cooled to -5°C. 1,3-Dichloro-1,1,3,3-tetraisopropyldisiloxane (1.13 mL, 3.53 mmol) was then added dropwise. After the addition was complete, the reaction mixture was heated to 25°C and stirred for 20 hours. The reaction solution was concentrated under reduced pressure to remove the solvent, and the residue was purified by silica gel column chromatography (eluent: PE / EA (v / v) = 2 / 3) to obtain compound 1-2 (1.38 g, 75.3%) as a white solid. MS (ESI, pos. ion) m / z: 534.3 [M+H] + .

[0283] Step 2: Synthesis of Compound 1-3

[0284] Compound 1-2 (1.08 g, 2.02 mmol) and N,N-dimethylformamide dimethyl acetal (0.48 g, 4.04 mmol) were added to toluene (15 mL) and stirred at 50°C for 4 h. After the reaction was complete, the mixture was concentrated under reduced pressure to obtain compound 1-3 as a white foamy solid (1.19 g, 100%). MS (ESI, pos. ion) m / z: 589.3 [M+H] + ; 1 H NMR(599MHz,DMSO-d6)δ8.95(s,1H),8.15(s,1H),6.90(d,J=4.4Hz,1H),6.80(d ,J=4.5Hz,1H),6.49(d,J=5.7Hz,1H),4.58(dd,J=5.7,4.4Hz,1H),4.23–4.12(m ,3H),3.92(dd,J=13.2,2.5Hz,1H),3.25(s,3H),3.19(s,3H),1.06–1.04(m,7H) ,1.01(dd,J=7.2,2.0Hz,6H),0.96(dd,J=8.8,7.0Hz,8H),0.89(t,J=7.6Hz,7H).

[0285] Step 3: Synthesis of Compound 1-4

[0286] Compound 1-3 (0.84 g, 1.43 mmol) was added to N,N-dimethylformamide (10 mL), cooled to 0°C, and then iodomethane (0.41 g, 2.86 mmol) and sodium hydride (0.11 g, 2.86 mmol, 60%) were added sequentially. The reaction was stirred at 0°C for 20 min. After the reaction was complete, the reaction solution was poured into saturated NH4Cl solution and extracted with EA. The organic phase was concentrated, and the residue was purified by silica gel column chromatography (EA / PE (v / v) = 1 / 1) to obtain compound 1-4 as a white solid (0.71 g, 83%). MS (ESI, pos. ion) m / z: 603.40 [M+H] + .

[0287] Step 4: Synthesis of Compound 1-5

[0288] Compound 1-4 (5.1 g, 8.46 mmol), tetrahydrofuran (50 mL), and a tetrabutylammonium fluoride solution in tetrahydrofuran (9.48 mL, 9.48 mmol, 1 M) were mixed and stirred at room temperature. After completion of the reaction, the mixture was concentrated under reduced pressure. The resulting residue was purified by silica gel column chromatography (MeOH / DCM (v / v) = 1 / 20) to obtain compound 1-5 (2.4 g, 79%) as a white solid. MS (ESI, pos. ion) m / z: 361.3 [M+H] + .

[0289] Step 5: Synthesis of Compound 1-6

[0290] Compound 1-5 (2.4 g, 6.66 mmol), dichloromethane (50 mL), triethylamine (2.02 g, 19.98 mmol), and 4-dimethylaminopyridine (0.081 g, 0.67 mmol) were mixed and then cooled to 0°C. 4,4'-bismethoxytrityl chloride (2.71 g, 7.99 mmol) was added portionwise. The resulting reaction mixture was warmed to room temperature and stirred for 3 h. The temperature was then lowered to 0°C, and 4,4'-bismethoxytrityl chloride (1.35 g) was added in two portions. The reaction mixture was stirred at 0°C for another 2 h. The reaction system was diluted with MeOH (1 mL) and DCM (100 mL), washed sequentially with saturated sodium bicarbonate solution and saturated sodium chloride solution. The organic phase was dried over anhydrous sodium sulfate and concentrated under reduced pressure. The resulting residue was purified on a silica gel column (EA / PE (v / v) = 2 / 1) to afford compound 1-6 (4.0 g, 91%) as a light yellow solid. MS (ESI, pos.ion) m / z: 663.7 [M+H] + .

[0291] Step 6: Synthesis of Compound 1

[0292] Compound 1-6 (2.0 g, 3.02 mmol) and 1H-tetrazole (0.25 g, 3.62 mmol) were added to dichloromethane (40 mL) under nitrogen protection. Bis(diisopropylamino)(2-cyanoethoxy)phosphine (1.92 mL, 6.04 mmol) was then added dropwise. The mixture was stirred at room temperature for 4 h. After the reaction, DCM (20 mL) and saturated sodium bicarbonate solution (10 mL) were added. The organic phase was washed with saturated brine, dried over anhydrous sodium sulfate, and concentrated under reduced pressure. The resulting residue was purified by silica gel column chromatography (EA / PE (v / v) = 4 / 1) to obtain compound 1 (2.13 g, 82%).

[0293] MS (ESI, pos.ion) m / z: 864.9 [M+H] + ;

[0294] 1 H NMR(400MHz, CDCl3)δ8.84(s,1H),8.00(d,J=12.0Hz,1H),7.45–7.39(m,2H),7.34–7.28(m,4H),7.22(qd,J=7.6,6.4,3.5Hz, 3H),7.02(dd,J=6.8,4.5Hz,1H),6.92(dd,J=4.6,3.1Hz,1H),6.78(td,J=8.5,4.4Hz,4H),4.93(dd,J=25.0,5.0Hz,1H),4.64 –4.43(m,2H),4.05–3.88(m,2H),3.79(dd,J=3.7,2.4Hz,6H),3.60(d,J=6.3Hz,4H),3.48(dd,J=10.5,3.6Hz,1H),3.27(s,3H ),3.24(s,3H),2.66(d,J=6.4Hz,1H),2.06(s,1H),1.28(t,J=7.1Hz,2H),1.19(dd,J=6.8,4.1Hz,8H),1.04(d,J=6.8Hz,4H).

[0295] 31 P NMR (162MHz, CDCl3) δ150.01,149.80.

[0296] Example 2: Synthesis of carrier (compound DAW40007-3)

[0297] Step 1: Synthesis of compound 2-2

[0298] Compound 2-1 (2.50 g, 28.05 mmol) and triethylamine (7.8 mL, 56.1 mmol) were dissolved in DCM (120 mL), and benzyl chloroformate (9.57 g, 56.1 mmol) was added dropwise at 0°C. After the addition, the reaction mixture was warmed to room temperature and stirred for 20 h. Saturated ammonium chloride solution (50 mL) was added for dilution. The layers were separated, the aqueous phase was discarded, and the organic phase was concentrated. The resulting residue was purified by silica gel column chromatography (MeOH / DCM (V / V) = 1 / 30) to obtain compound 2-2 (2.96 g, 47.2%) as a white solid.

[0299] MS (ESI, pos.ion) m / z: 224.2 [M+H] + ;

[0300] 1 H NMR(400MHz, CDCl3)δ7.37(d,J=4.2Hz,5H),5.11(s,2H),5.00(s,1H),4.19–4.14(m,1H),3.70–3.64(m, 2H), 3.24 (t, J=6.4Hz, 2H), 3.15 (q, J=4.6Hz, 1H), 1.90 (dq, J=14.2, 5.0, 4.3Hz, 2H), 1.77–1.71 (m, 1H).

[0301] Step 2: Synthesis of Compound 2-4

[0302] Compound 2-3 (1.5 g, 4.56 mmol) and compound 2-2 (1.22 g, 5.47 mmol) were dissolved in 1,2-dichloroethane (30 mL), and 3A molecular sieves (2.0 g) were added. The mixture was stirred at room temperature for 10 min. TMSOTf (0.51 g, 2.28 mmol) was then added, and the reaction mixture was stirred at room temperature for 18 h. The reaction mixture was poured into saturated sodium bicarbonate solution (100 mL), extracted with DCM (100 mL), washed with saturated brine (100 mL), dried over anhydrous sodium sulfate, and the solvent evaporated under reduced pressure. The resulting residue was purified by silica gel column chromatography (PE / EA (V / V) = 2 / 1 to 0 / 1) to afford compound 2-4 (1.8 g, 71.51%) as a light brown oil. MS (ESI, pos. ion) m / z: 553.3 [M+H] + .

[0303] Step 3: Synthesis of Compound 2-5

[0304] Compound 2-4 (0.57 g, 1.03 mmol) and palladium carbon (0.11 g, 0.1 mmol, 10%) were added to THF (10 mL), followed by the addition of TFA (0.12 g, 1.03 mmol). The mixture was then replaced with hydrogen three times and stirred at room temperature under a hydrogen atmosphere for 19 h. After the reaction was complete, the mixture was filtered through celite and the solvent was evaporated under reduced pressure to obtain compound 2-5 (0.55 g, 100.32%) as a light brown oil. MS (ESI, pos. ion) m / z: 419.3 [M-TFA+H] + .

[0305] Step 4: Synthesis of Compound 2-7

[0306] Compound 2-6 (0.46 g, 2.29 mmol, purchased from Shanghai Bid Pharmaceutical Technology Co., Ltd.) and compound 2-5 (1.16 g, 2.18 mmol) were dissolved in DCM (30 mL). HOBT (0.46 g, 3.44 mmol), HBTU (1.30 g, 3.44 mmol), and DIPEA (2.66 mL, 16.03 mmol) were added sequentially. The reaction mixture was reacted at room temperature for 16 h. After the reaction, water (20 mL) and DCM (50 mL × 2) were added sequentially. The organic phase was washed with saturated sodium bicarbonate solution (30 mL) and saturated brine (20 mL). The solvent was evaporated under reduced pressure, and the resulting residue was purified by silica gel column chromatography (MeOH / EA (v / v) = 1 / 20) to obtain 2-7 (1.0 g, 72.7% yield) as a white solid.

[0307] MS (ESI, pos.ion) m / z: 602.3 [M+H] + ;

[0308] 1 H NMR (400MHz, CD3OD) δ5.39–5.33(m,1H),5.07(dd,J=11.2,3.4Hz,1H),4.58(d,J= 8.4Hz,1H),4.21–4.09(m,3H),4.04(t,J=6.7Hz,1H),3.89(dt,J=10.4,5.1Hz,1H ),3.60–3.50(m,1H),3.30–3.13(m,2H),2.16(s,3H),2.04(s,3H),1.97(s,3H),1 .94(s,3H),1.67–1.56(m,4H),1.48(s,9H),1.41–1.37(m,2H),1.02–0.98(m,2H).

[0309] Step 5: Synthesis of compound 2-8

[0310] Compound 2-7 (0.72 g, 1.17 mmol) was dissolved in DCM (8 mL), and then TFA (0.87 mL, 11.7 mmol) was added. The reaction mixture was stirred at 25 °C for 16 h, and the solvent was concentrated to give brown oily compound 2-8 (0.74 g, 103.1%).

[0311] MS (ESI, pos.ion) m / z: 502.2 [M+H] + ;

[0312] 1 H NMR (400MHz, CD3OD) δ5.36 (d, J=3.3Hz, 1H), 5.08 (dd, J=11.3, 3.3Hz, 1H), 4.5 8(d,J=8.4Hz,1H),4.16–4.10(m,3H),4.08–4.02(m,1H),3.92–3.85(m,1H),3 .58–3.50(m,1H),3.26–3.20(m,2H),2.16(s,3H),2.04(d,J=5.2Hz,6H),1.98 (s,3H),1.97(s,3H),1.61–1.56(m,4H),1.54–1.52(m,2H),1.42–1.38(m,2H).

[0313] Step 6: Synthesis of Compound 2-10

[0314] Compound 2-9 (0.19 g, 0.30 mmol) and compound 2-8 (0.50 g, 0.99 mmol) were dissolved in DCM (30 mL), and HOBT (0.17 g, 1.26 mmol), HBTU (0.48 g, 1.26 mmol), and DIPEA (0.5 mL, 3.0 mmol) were added sequentially. The reaction mixture was stirred at 30°C for 3 h. After completion of the reaction, water (20 mL) was added to quench the reaction, and the mixture was extracted with DCM (100 mL × 2). The organic phases were combined and washed sequentially with saturated sodium bicarbonate solution (40 mL) and saturated sodium chloride solution (40 mL), dried over anhydrous sodium sulfate, and the solvent was evaporated under reduced pressure. The resulting residue was separated and purified by silica gel column chromatography (DCM / MeOH (v / v) = 10 / 1) to obtain compound 2-10 (0.23 g, yield 37%) as a white solid. MS(ESI,pos.ion)m / z:1046.3[M / 2+H] + ;

[0315] 1H NMR (400MHz, CD3OD) δ7.78(t,J=5.8Hz,2H),7.38–7.36(m,3H),5.36(d,J=3.4Hz,3H),5.13(s,2H),5.08(dd,J=11.2, 3.4Hz,3H),4.58(d,J=8.4Hz,3H),4.21–4.08(m,9H),4.04(t,J=6.7Hz,3H),3.93–3.82(m,3H),3.73–3.66(m,12H),3. 60–3.52(m,3H),3.29–3.18(m,6H),2.52(t,J=6.0Hz,6H),2.38(t,J=7.4Hz,2H),2.20(t,J=7.7Hz,2H),2.16(s,9H), 2.04(s,9H),1.97(s,9H),1.95(s,9H),1.62–1.56(m,12H),1.50–1.42(m,6H),1.35–1.27(m,16H),1.04–0.97(m,6H).

[0316] Step 7: Synthesis of compound 2-11

[0317] Compound 2-10 (0.20 g, 0.094 mmol) was dissolved in methanol (10 mL), followed by the addition of Pd / C (10 mg, 10%). The atmosphere was replaced with hydrogen three times, and the reaction mixture was stirred at room temperature for 11 h under a hydrogen atmosphere. After the reaction, the reaction mixture was filtered through celite, and the filtrate was evaporated to dryness under reduced pressure to afford compound 2-11 (0.19 g, 100%) as a white solid.

[0318] MS(ESI,pos.ion)m / z:1001.1[M / 2+H] + .

[0319] Step 8: Synthesis of compound DAW40007-1

[0320] Compound 2-11 (0.28 g, 0.14 mmol) was dissolved in DCM (20 mL), and HOBT (0.038 g, 0.28 mmol), HBTU (0.080 g, 0.21 mmol), DIPEA (0.054 g, 0.42 mmol) and compound 13 (0.068 g, 0.16 mmol) were added in sequence. The reaction mixture was stirred at room temperature for 13 h. After the reaction was completed, water (10 mL) was added to quench the reaction, and the mixture was extracted with DCM (20 mL). The organic phase was washed with saturated sodium bicarbonate solution (10 mL), and the solvent was evaporated under reduced pressure. The resulting residue was dissolved in acetonitrile (10 mL) and separated by reverse phase preparative column (acetonitrile / water solution (v / v) = 43% to 60%, 50min), salt was added to the solution containing the product after preparative separation to saturate the solution, the organic phase was separated, the aqueous phase was extracted with acetonitrile (100mL×2), the organic phases were combined, and the combined organic phases were dried over anhydrous sodium sulfate. The solvent was evaporated under reduced pressure, acetonitrile (30mL) was added to the residue, and then dried over sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure to obtain a light yellow solid compound DAW40007-1 (0.080g, yield 24%).

[0321] MS(ESI,neg.ion)m / z:2400.18[MH] - ;

[0322] 1H NMR (400MHz, DMSO-d6) δ8.31 (s, 3H), 7.81 (d, J = 9.2Hz, 3H), 7.57 (t, J = 6.0 Hz,3H),7.35–7.26(m,4H),7.20(td,J=8.9,3.0Hz,5H),6.95(s,1H),6.88( ddd,J=8.8,5.8,2.2Hz,4H),5.22(d,J=3.4Hz,3H),4.97(dd,J=11.2,3.5H z,4H),4.49(d,J=8.5Hz,3H),4.40(d,J=4.8Hz,1H),4.15(s,1H),4.07–4.0 0(m,9H),3.88(dt,J=11.2,8.8Hz,3H),3.74(s,9H),3.59–3.48(m,12H),3 .17(dd,J=8.8,5.0Hz,1H),3.10–2.95(m,8H),2.35(t,J=6.3Hz,6H),2.10( s,9H),2.08(s,3H),2.04(d,J=4.7Hz,2H),2.00(s,9H),1.89(s,9H),1.78( s,9H),1.40(d,J=12.2Hz,17H),1.31–1.16(m,18H),0.79(q,J=3.2Hz,6H).

[0323] Step 9: Synthesis of compound DAW40007-2

[0324] Compound DAW40007-1 (0.080 g, 0.033 mmol) was dissolved in DCM (10 mL), and DIPEA (0.029 mL, 0.17 mmol), succinic anhydride (0.008 g, 0.083 mmol) and DMAP (0.014 g, 0.12 mmol) were added. The mixture was stirred at 40°C for 5 h, and succinic anhydride (10 mg) was added. After the reaction was continued for 16 h, DCM (10 mL), succinic anhydride (10 mg) and DIPEA (0.05 mL) were added. The mixture was stirred for another 9 h, and then succinic anhydride (10 mg) was added. After the reaction was continued for another 10 h, DCM (20 mL) was added to dilute the mixture, and the mixture was washed with saturated sodium bicarbonate solution (10 mL). The aqueous phase was discarded, and the organic phase was dried over anhydrous sodium sulfate. The solvent was concentrated under reduced pressure to obtain compound DAW40007-2 (0.08 g, 96.07%) as a white solid. MS(ESI,neg.ion)m / z:2500.12[MH] - .

[0325] Step 10: Synthesis of compound DAW40007-3

[0326] Compound DAW40007-2 (0.08 g, 0.032 mmol), HBTU (0.015 g, 0.04 mmol), and DIPEA (0.011 mL, 0.064 mmol) were dissolved in ACN (5 mL) and stirred at room temperature for 5 min. The mixture was then transferred to a solid-phase synthesizer containing 0.35 g of H2N-CPG (purchased from Hebei Dinaxingke) and shaken for 22.5 h. The mixture was filtered, and the filter cake was rinsed with DCM / MeOH (V / V=9 / 1, 10 mL) and DCM (10 mL), and dried under reduced pressure. The resulting filter cake was diluted in 25% Ac2O / Py solution (5 mL) and stirred for 3 h. The mixture was filtered, and the filter cake was rinsed with DCM / MeOH (V / V=9 / 1, 10 mL) and DCM (10 mL) in turn. The mixture was dried under reduced pressure to give a white solid DAW40007-3 (0.357 g) with a measured loading of 14.95 μmol / g.

[0327] It is well known in the art that DAW40007-4 is the residue after DAW40007-3 undergoes a chemical reaction, and is bound to the nucleic acid through a covalent bond.

[0328] Synthesis of compound L96

[0329] Compound L96 was prepared according to the method described in patent application WO2014025805A1.

[0330] The structure of the L96 conjugated group is:

[0331] Example 3: Synthesis of double-stranded siRNA and double-stranded siRNA conjugates

[0332] 1. Synthesis of double-stranded siRNA without conjugated groups

[0333] The steps for synthesizing the sense and antisense strands of siRNA without conjugated groups are as follows:

[0334] The synthesis was completed according to the theoretical yield of 1 μmol. Weigh 1 μmol of solid support CPG (purchased from Hebei Dina Xingke). All 2'-modified RNA phosphoramidite monomers and auxiliary reagents were commercially obtained, and all phosphoramidite monomers were provided in 0.1M anhydrous acetonitrile solution. For oligonucleotides with phosphate backbone thiolation modification, 0.1M DDTT solution was used as the thiolation reagent. 5-Ethylthio-1H-tetrazole acetonitrile solution (0.25M) was used as the activator (purchased from Suzhou Kelema), 0.02M iodine in pyridine / water solution was used as the oxidant, and 3% trichloroacetic acid in dichloromethane was used as the deprotection reagent. They were placed in the designated reagent position corresponding to the KA-H8 model DNA / RNA automatic synthesizer. Set the synthesis program and enter the specified oligonucleotide base sequence. After checking that everything is correct, start the cyclic oligonucleotide synthesis. The coupling time for each step is 6 minutes, and the thiolation time is 6 minutes. After automatic circulation, an oligonucleotide containing solid support CPG is obtained.

[0335] The CPG-containing nucleotides obtained above were blown dry with dry argon, then transferred to a 2 mL EP tube and 28% ammonia solution (1.8 mL) was added and heated at 55°C for 5 to 18 hours. Filter, wash the filter cake with water (0.5 mL), combine the filtrates, and concentrate under reduced pressure to obtain a white or yellow colloidal solid. After reverse phase preparative purification, the prepared solution was concentrated and passed through a gel column to remove excess salt to obtain the oligonucleotide. The concentration of the obtained oligonucleotide was determined by a micro-UV spectrophotometer (SPECTRO stat Nano). Mass spectrometry detection and analysis were performed on an Agilent 6530LC-MS Q-Tof system. After primary scanning, the nucleic acid molecular weight was calculated after deconvolution.

[0336] Annealing step:

[0337] The double-stranded siRNA sense strand synthesized above was mixed with the antisense strand synthesized above in equimolar amounts, heated to 95°C, maintained at this temperature for 10 minutes, and then slowly cooled to room temperature. The target double-stranded siRNA was then lyophilized.

[0338] 2. Synthesis of siRNA conjugates:

[0339] The synthesis of the antisense strand was obtained by referring to the above-mentioned method for synthesizing the sense strand and antisense strand without the conjugated group.

[0340] Synthesis of the sense strand: The general solid support CPG was replaced with the conjugated group-solid support CPG prepared in the present invention (such as compound DAW40007-3), and the sense strand of the double-stranded siRNA conjugate of the present invention was prepared by referring to the antisense strand synthesis method.

[0341] Annealing step:

[0342] The sense strand of the double-stranded siRNA conjugate synthesized above was mixed with the antisense strand synthesized above in equimolar amounts, heated to 95°C, maintained at this temperature for 10 minutes, and then slowly cooled to room temperature. The target siRNA conjugate was then lyophilized.

[0343] The double-stranded siRNA and double-stranded siRNA conjugates synthesized above are shown in Table 1-A.

[0344] Table 1-A: Double-stranded siRNA and double-stranded siRNA conjugates synthesized by the present invention

[0345] The capital letters C, G, U, and A represent the base composition of natural nucleotides; the lowercase letters c, g, u, and a represent that the 2-position of the ribose sugar on the nucleotide represented by the corresponding capital letter is modified by a methoxy group; the underline under the capital letter represents that the 2-position of the ribose sugar on the nucleotide represented by the letter is modified by a fluorine group; the spacer "●" indicates that the two nucleotide residues adjacent to the spacer "●" are connected by a phosphorothioate group; Agn is adenosine-glycol nucleic acid (GNA); Y in double-stranded siRNA represents X in double-stranded siRNA represents

[0346] Example 4 Cellular activity and cytotoxicity testing of nucleic acids or conjugates of the present invention

[0347] Hepatoma cells (Hep AD38) were cultured in DMEM medium containing 10% fetal bovine serum in a 5% CO2, 37°C incubator. Hepatoma cells were used for experiments when they were in the logarithmic growth phase and in good condition (70% confluence). 1.5×10 cells were seeded per well of a 96-well plate. 4 Cells were transfected with different double-stranded siRNAs of different concentrations in Table 1 of Example 3 according to the instructions of RNAiMAX transfection reagent (Thermo Fisher), and then incubated for 72 hours at 37°C and 5% CO2. HBsAg expression and cytotoxicity were detected using HBsAg ELISA kit (Shanghai Kehua) and CCK8 kit (DOJINDO), respectively. The double-stranded siRNA reagent of the present invention has good inhibitory activity against HBsA and is significantly better than the HBsA inhibitory activity of the control S144. It can be seen that the introduction of nucleotide residue Y in the double-stranded siRNA described in the present application has a significant effect on improving the activity of the double-stranded siRNA, and the double-stranded siRNA described in the present application has low cytotoxicity. The HBsA inhibitory activity and cytotoxicity results of some double-stranded siRNAs or their conjugates are shown in Table 2.

[0348] Table 2: Inhibitory activity and cytotoxicity results of partially double-stranded siRNA or conjugates of the present invention

[0349] Among them, the capital letters C, G, U, and A represent the base composition of natural nucleotides; the lowercase letters c, g, u, and a respectively indicate that the 2-position of the ribose on the nucleotide represented by the corresponding capital letter is modified by methoxy; the underline ___ below the capital letter indicates that the 2-position of the ribose on the nucleotide represented by the letter is modified by fluorine; the spacer "●" indicates that the two nucleotide residues adjacent to the spacer "●" are connected by a thiophosphate group.

[0350] Example 6: Evaluation of anti-hepatitis B virus (HBV) activity using the PHH in vitro infection model

[0351] The experimental steps are as follows

[0352] Transfection and drug addition: On day 0, resuscitated PHH were adjusted to an appropriate density (6.67E+05 cells / ml) and seeded into a 48-well cell culture plate at 1.32E+05 cells per well. On day 1, HBV subtype D was added to infect PHH (800GE / cell). On day 2, fresh medium was replaced. On day 4, the cell culture medium was discarded, the test substance was serially diluted to the desired concentration, and then transfected with Lipofectamine. TM RNAiMAX transfection was used to transfect cells. The starting concentration of the test substance was 500 pM, and the cells were diluted 5-fold. Seven concentrations were set in duplicate. Wells containing only the transfection reagent served as medium controls. Fresh medium without compound was replaced 4-5 hours after transfection. The final DMSO concentration in the medium was 2%. On day 6, fresh medium without compound was replaced. On day 8, cell supernatants were collected and cell viability was assessed using CCK-8.

[0353] Free uptake of the test substance: On day 0, the test substance was diluted to the desired concentration in enzyme-free water, starting at 500 nM. Five-fold dilutions were performed, each with 7 concentrations set in duplicate, and 22 μl was added to each well of the cell culture plate. Frozen PHH were revived and adjusted to an appropriate density (6.67E+05 cells / ml), with 1.32E+05 cells per well; the cells were plated and the test substance was freely uptaken into the cells. On day 1, the culture medium was changed and PHH were infected with HBV type D (800GE / cell). On day 2, fresh culture medium was replaced without virus and compound. The final DMSO concentration in the culture medium was 2%. On days 4 and 6, fresh culture medium was replaced without compound. On day 8, the cell supernatant was collected and cell viability was measured using CCK-8.

[0354] Sample testing: qPCR was used to detect the HBV DNA content in the cell culture supernatant; ELISA was used to detect the HBsAg and HBeAg content in the cell culture supernatant. The experimental results of the double-stranded siRNA conjugate of the present invention in reducing the levels of HBsAg, HBeAg, and DNA in cells are shown in Table 3.

[0355] Table 3: Experimental results of the double-stranded siRNA conjugates of the present invention in reducing the levels of HBsAg, HBeAg and DNA in cells

[0356] The experimental results showed that the double-stranded siRNA conjugate S146 had good inhibitory activity against HBsAg, HBeAg and DNA. Without the need for transfection, its inhibitory activity against HBsAg, HBeAg and DNA was significantly better than that of the control S148.

[0357] Example 6: Hepatitis B virus transgenic mouse experiment

[0358] 1. HBV-Tg transgenic mouse experiments

[0359] Experimental methods

[0360] Experimental animals: HBV-Tg transgenic mice, C57B / 6N-Tg (1.28HBV) / Vst, SPF-grade male, 6-8 weeks old, 16-20 g, purchased from Beijing Weitongda Biotechnology Co., Ltd., animal production certificate number: SCXK (Beijing) 2019-0002. The animals were raised by Beijing Weitongda Biotechnology Co., Ltd. and kept in single cages.

[0361] Animal grouping: According to the quantitative detection results of mouse serum HBsAg (primary) and HBeAg (secondary), the animals were stratified and randomly divided into groups, with 5 animals in each group.

[0362] Test Article Preparation and Administration: Calculate the required dosage of drug powder based on the purity of each test article. Add the appropriate saline solution at a dosing concentration of 0.6 mg / mL and vortex to mix until a colorless, transparent liquid is obtained. The day of the first dose is designated Day 0. All groups of animals received a single subcutaneous dose of 5 mL / kg on Day 0. If blood sampling is required on the day of dosing, administer the drug after blood collection.

[0363] Main Outcome Measures: Patients were weighed and blood was collected once on the 3rd, 7th, 14th, 21st, 28th, and 35th day, and serum was separated for determination of HBsAg and HBeAg levels.

[0364] Serum HBsAg and HBeAg Levels: After blood collection, serum was separated and diluted with PBS solution before testing. 10 μL of serum was collected from each sample and diluted to 500 μL (50-fold dilution) with PBS solution. Serum HBsAg and HBeAg levels were measured using a Hepatitis B e Antigen Assay Kit (Mike Biotech) and a Hepatitis B Surface Antigen Assay Kit (Mike Biotech), respectively.

[0365] Experimental results of HBV-Tg transgenic mice

[0366] In the HBV-Tg mouse model experiment, the inhibitory effect of the siRNA conjugate of the present invention on HBsAg is shown in Figure 1.

[0367] The experimental results showed that, compared to the vehicle control group, at a dose of 3 mg / kg, the test compound DAW30227 (double-stranded siRNA conjugate S146) exhibited significant inhibitory effects on HBsAg and also had a moderate inhibitory effect on HBeAg. Furthermore, the double-stranded siRNA conjugate S146 exhibited significantly superior HBsAg inhibitory activity compared to the control DAW30025 (siRNA conjugate S149).

[0368] 2. Hepatitis B virus AAV mouse experiment

[0369] Experimental methods:

[0370] Preparation and grouping of the rAAV8-1.3HBV / C57BL / 6 mouse model: A mouse model of persistent HBV infection was established by intravenous injection of rAAV8-1.3HBV (type C) into C57 mice. The AAV virus injection dose was 1E+11 vg / mouse. Six weeks after virus injection, blood was collected to measure serum HBeAg, HBsAg, and ALT levels. Based on the quantitative detection results of mouse serum HBsAg (primary) and HBeAg (secondary), 35 animals were randomly divided into stratified groups, with 5 animals per group.

[0371] Test Article Preparation and Administration: Calculate the required dosage of drug powder based on the purity of each test article. Add the appropriate saline solution at a dosing concentration of 0.6 mg / mL and vortex to mix until a colorless, transparent liquid is obtained. The day of the first dose is designated Day 0. All groups of animals received a single subcutaneous dose of 5 mL / kg on Day 0. If blood sampling is required on the day of dosing, administer the drug after blood collection.

[0372] Main Outcome Measures: Patients were weighed and blood was collected once on the 3rd, 7th, 14th, 21st, and 28th day, and serum was separated for determination of HBsAg and HBeAg levels.

[0373] Serum HBsAg and HBeAg Levels: After blood collection, serum is separated and diluted with PBS solution before testing. 10 μL of serum from each sample is diluted to 500 μL with PBS solution (50-fold dilution). Serum HBsAg and HBeAg levels are measured using the Hepatitis B e Antigen Assay Kit and the Hepatitis B Surface Antigen Assay Kit, respectively.

[0374] Results of Hepatitis B Virus AAV Mouse Experiment

[0375] In the Tg / HBV mouse model experiment, the inhibitory effect of the siRNA conjugate of the present invention on HBsAg is shown in Figure 2.

[0376] The experimental results showed that, compared to the vehicle control group, at a dose of 3 mg / kg, the test compound DAW30335 (siRNA conjugate S147) exhibited a significant inhibitory effect on HBsAg and also had a moderate inhibitory effect on HBeAg. Furthermore, the inhibitory activity of siRNA conjugate S147 against HBsAg was significantly superior to that of the control compounds DAW30025 (siRNA conjugate S149) and DAW30336 (siRNA conjugate S151).

[0377] Example 7: Toxicity experiment of the conjugate of the present application in rats after subcutaneous injection

[0378] Experimental methods:

[0379] Rats were dosed five times for a total of 29 days. Clinical observations were performed. Blood was collected from the abdominal aorta after anesthesia before autopsy. Biochemical tests included ALT, AST, ALP, CK, UREA, CREA, TP, ALB, GLU, TBIL, DBIL, CHO, TG, Na, K, Cl, A / G, and GLB. Hematology tests included WBC, RBC, HB, HCT, MCV, MCH, MCHC, RDW, PLT, MPV, WBC classification and percentage. Coagulation tests included PT, APTT, and FIB. Histological evaluations also included organ weights, including the aorta, esophagus, stomach, duodenum, cecum, colon, ileum, jejunum, rectum, lung (with main bronchus attached), mesenteric lymph nodes, pancreas, pituitary gland, eyeball, thyroid / parathyroid gland, salivary gland, prostate, bladder, seminal vesicle, femur, sternum, skin and muscle at the administration site (marked at the time of the last administration), and gross abnormalities.

[0380] Statistical Methods: SPSS 16.0 was used for statistical analysis. Means and standard deviations were calculated for body weight, blood biochemistry, hematology, organ weights, and coefficients for each group, and statistical analysis was performed according to the following methods: ① Data homogeneity was first tested using Levene's test. If the data were homogeneous (P>0.05), a one-way analysis of variance (ANOVA) was performed. If the Levene's test was significant (p≤0.05), a Kruskal-Wallis test was performed. ② If the ANOVA result was significant (p≤0.05), a multiple comparison test was performed using the Dunnett parametric test. If the ANOVA result was not significant (p>0.05), statistical analysis was terminated. ③ If the Kruskal-Wallis test was significant (p≤0.05), a rank-transformed Dunnett test was performed. If the Kruskal-Wallis test was not significant (p>0.05), statistical analysis was terminated. Clinical symptom observations, food intake, and anatomical observation data were not statistically processed.

[0381] Experimental conclusion: The experiment showed that clinical observation, blood biochemistry, hematology, organ weight and tissue pathology results overall showed that the siRNA conjugate of the present invention has good safety.

[0382] Although the present invention has been described in detail above using general explanations, specific embodiments, and experiments, it will be apparent to those skilled in the art that modifications and improvements may be made based on the present invention. Therefore, such modifications and improvements, which do not depart from the spirit of the present invention, are intended to be within the scope of protection claimed herein.

Claims

1. A double-stranded siRNA, a conjugate thereof or a salt thereof, wherein: The double-stranded siRNA comprises a sense strand and an antisense strand, and the double-stranded siRNA comprises one or more Y, wherein Y is Each nucleotide and Y in the double-stranded siRNA is independently modified or unmodified.

2. The double-stranded siRNA, its conjugate or its salt according to claim 1, wherein The antisense strand comprises a sequence as shown in 5'-UGUGAAGCGAAGUGCACACUU-3' (SEQ ID NO: 40), or a sequence in which one or more nucleotide residues are replaced by Y in the sequence as shown in SEQ ID NO: 40; wherein each nucleotide and Y in the antisense strand are independently modified or unmodified, and the length of the antisense strand does not exceed 23 nucleotides.

3. The double-stranded siRNA, its conjugate or its salt according to claim 1 or 2, wherein: The sense strand comprises a sequence as shown in 5'-GUGUGCACUUCGCUUCACA-3' (SEQ ID NO: 20), or a sequence in which one or more nucleotide residues are replaced by Y in the sequence as shown in SEQ ID NO: 20, wherein each nucleotide and Y in the sense strand are independently modified or unmodified, and the length of the sense strand does not exceed 23 nucleotides.

4. The double-stranded siRNA, its conjugate or its salt according to any one of claims 1 to 3, wherein 70%, 75%, 80%, 85%, 90% or more of the nucleotides and Y in the sense strand or antisense strand are modified; optionally, every nucleotide and Y in the double-stranded siRNA is modified.

5. The double-stranded siRNA, its conjugate or its salt according to any one of claims 1 to 4, wherein the modification is selected from at least one of the following: 2'-methoxy modification, 2'-methoxyethyl modification, 2'-fluoro modification, thiophosphate linkage, 2'-deoxy modification, 2'-amino modification, locked nucleic acid modification, unlocked nucleic acid modification, ethylene glycol nucleic acid modification and 5'-vinyl phosphate modification.

6. The double-stranded siRNA, its conjugate or its salt according to any one of claims 1 to 5, wherein The sense strand comprises a sequence in which 0, 1, 2, 3, 4 or 5 nucleotide residues are replaced with Y in the sequence as shown in SEQ ID NO: 20, wherein each nucleotide and Y in the sense strand are independently modified or unmodified.

7. The double-stranded siRNA, its conjugate or its salt according to any one of claims 1 to 6, wherein The antisense strand comprises a sequence in which 0, 1, 2, 3, 4 or 5 nucleotide residues are replaced with Y in the sequence as shown in SEQ ID NO: 40, wherein each nucleotide and Y of the antisense strand are independently modified or unmodified.

8. The double-stranded siRNA, its conjugate or its salt according to any one of claims 1 to 7, wherein The Y substitution occurs at positions 1 to 19 at the 5' end of the sequence shown in SEQ ID NO:

20.

9. The double-stranded siRNA, its conjugate or its salt according to any one of claims 1 to 8, wherein The Y substitution occurs at positions 1 to 21 at the 5' end of the sequence shown in SEQ ID NO:

40.

10. The double-stranded siRNA, its conjugate or its salt according to any one of claims 1 to 9, wherein: The sense strand comprises a sequence in which 0, 1, 2, 3, 4 or 5 nucleotide residues are replaced by Y in the sequence as shown in 5'-g●u●guGcACUucgcuucaca-3' (SEQ ID NO: 19), wherein each nucleotide and Y of the sense strand are independently modified or unmodified, the Y replacement occurs at positions 1 to 19 at the 5' end of the SEQ ID NO: 19, and the length of the sense strand does not exceed 23 nucleotides.

11. The double-stranded siRNA, its conjugate or its salt according to any one of claims 1 to 10, wherein: The antisense strand comprises a sequence in which 0, 1, 2, 3, 4 or 5 nucleotide residues are replaced by Y in the sequence shown as 5'-u●G●ugaAgCGaaguGcAcac●u●u-3' (SEQ ID NO:36), wherein each nucleotide and Y of the antisense strand are independently modified or unmodified, the Y replacement occurs at positions 1 to 21 at the 5' end of the antisense strand SEQ ID NO:36, and the length of the antisense strand does not exceed 23 nucleotides.

12. The double-stranded siRNA, its conjugate or its salt according to any one of claims 1 to 10, wherein: The antisense strand comprises a sequence in which 0, 1, 2, 3, 4 or 5 nucleotide residues are replaced by Y in the sequence as shown in 5'-u●G●uga(Agn)gCGaaguGcAcac●u●u-3' (SEQ ID NO:33), wherein each nucleotide and Y of the antisense strand are independently modified or unmodified, the Y replacement occurs at the 1st to 21st positions at the 5' end of the sequence as shown in SEQ ID NO:33, and the length of the antisense strand does not exceed 23 nucleotides.

13. The double-stranded siRNA, its conjugate or its salt according to any one of claims 1 to 12, wherein the sense strand comprises one of the following nucleotide sequences: SEQ ID NO:1, SEQ ID NO:2, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:6, SEQ ID NO:7, SEQ ID NO:8, SEQ ID NO:9, SEQ ID NO:10, SEQ ID NO:11, SEQ ID NO:12, SEQ ID NO:13, SEQ ID NO:14, SEQ ID NO:15, SEQ ID NO:16, SEQ ID NO:17, SEQ ID NO:18, SEQ ID NO:19 and SEQ ID NO:21; The sense strand has a length of no more than 23 nucleotides.

14. The double-stranded siRNA, its conjugate or its salt according to any one of claims 1 to 13, wherein the antisense strand comprises one of the following nucleotide sequences: SEQ ID NO:22, SEQ ID NO:23, SEQ ID NO:24, SEQ ID NO:25, SEQ ID NO:26, SEQ ID NO:27, SEQ ID NO:28, SEQ ID NO:29, SEQ ID NO:30, SEQ ID NO:31, SEQ ID NO:32, SEQ ID NO:33, SEQ ID NO:34, SEQ ID NO:35, SEQ ID NO:36, SEQ ID NO:37, SEQ ID NO:38 and SEQ ID NO:39; The sense strand has a length of no more than 23 nucleotides.

15. The double-stranded siRNA, its conjugate or its salt according to any one of claims 1 to 14, wherein: The double-stranded siRNA comprises one of the following: A sense strand having a nucleotide sequence as shown in SEQ ID NO: 15 and an antisense strand having a nucleotide sequence as shown in SEQ ID NO: 25, wherein the length of the sense strand and the antisense strand is each independently no more than 23 nucleotides; A sense strand having a nucleotide sequence as shown in SEQ ID NO: 17 and an antisense strand having a nucleotide sequence as shown in SEQ ID NO: 25, wherein the length of the sense strand and the antisense strand is each independently no more than 23 nucleotides; A sense strand having a nucleotide sequence as shown in SEQ ID NO: 15 and an antisense strand having a nucleotide sequence as shown in SEQ ID NO: 26, wherein the length of the sense strand and the antisense strand is each independently no more than 23 nucleotides; A sense strand having a nucleotide sequence as shown in SEQ ID NO: 16 and an antisense strand having a nucleotide sequence as shown in SEQ ID NO: 26, wherein the length of the sense strand and the antisense strand is each independently no more than 23 nucleotides; A sense strand having a nucleotide sequence as shown in SEQ ID NO: 17 and an antisense strand having a nucleotide sequence as shown in SEQ ID NO: 26, wherein the length of the sense strand and the antisense strand is each independently no more than 23 nucleotides; A sense strand having a nucleotide sequence as shown in SEQ ID NO: 15 and an antisense strand having a nucleotide sequence as shown in SEQ ID NO: 27, wherein the length of the sense strand and the antisense strand is each independently no more than 23 nucleotides; A sense strand comprising the nucleotide sequence shown in SEQ ID NO: 16 and an antisense strand comprising the nucleotide sequence shown in SEQ ID NO: 27, wherein the length of the sense strand and the antisense strand is each independently no more than 23 nucleotides; A sense strand having a nucleotide sequence as shown in SEQ ID NO: 17 and an antisense strand having a nucleotide sequence as shown in SEQ ID NO: 27, wherein the length of the sense strand and the antisense strand is each independently no more than 23 nucleotides; A sense strand comprising the nucleotide sequence shown in SEQ ID NO: 16 and an antisense strand comprising the nucleotide sequence shown in SEQ ID NO: 28, wherein the length of the sense strand and the antisense strand is each independently no more than 23 nucleotides; The positive strand has the nucleotide sequence shown in SEQ ID NO: 17 and the negative strand has the nucleotide sequence shown in SEQ ID NO:

28. A sense strand, wherein the sense strand and the antisense strand are each independently no longer than 23 nucleotides; or A sense strand having a nucleotide sequence shown in SEQ ID NO: 18 and an antisense strand having a nucleotide sequence shown in SEQ ID NO: 28, wherein the length of the sense strand and the antisense strand is independently no more than 23 nucleotides.

16. The double-stranded siRNA, its conjugate or its salt according to any one of claims 1 to 15, wherein: The double-stranded siRNA or its conjugate is selected from one of S1 to S143, S146, S147 and S150.

17. The double-stranded siRNA, its conjugate or its salt according to any one of claims 1 to 16, wherein: The double-stranded siRNA conjugate is a conjugate of the double-stranded siRNA and the conjugation group L96 or DAW40007-4, and the structures of the conjugation group L-96 and DAW40007-4 are respectively:

18. The double-stranded siRNA, its conjugate or its salt according to claim 17, wherein: The conjugated group is conjugated to the 3' end or 5' end of the sense strand of the double-stranded siRNA, preferably to the 3' end of the sense strand of the double-stranded siRNA.

19. The double-stranded siRNA, its conjugate or its salt according to claim 17 or 18, wherein: The double-stranded siRNA is linked to the conjugated group via a phosphate group, a phosphorothioate group or a phosphate group.

20. A nucleotide residue Y having the structure:

21. A compound having a structure as shown in formula (I), or a stereoisomer, tautomer or acceptable salt of the compound as shown in formula (I), R 1 is methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl or tert-butyl, each of which is independently optionally substituted with 1, 2, 3 or 4 substituents selected from deuterium, hydroxyl, cyano, F, Cl, Br, I, methoxy, ethoxy, 1-propoxy and 2-propoxy; Z and Y 1 are independently H, deuterium, a hydroxyl protecting group, HOC(=O)(CH2) j C(=O)-、MC(=O)(CH2) j C(═O)—, a phosphate group, a phosphorothioate group, a phosphite amide group, or a hydrogen phosphate group; M is a solid support, preferably a hydroxyl- or amino-functionalized solid support, more preferably a resin or CPG, further preferably a macroporous resin or CPG, further preferably an aminomethyl resin, a hydroxyl resin or -NHCPG; R is -NHR 2 or -N=CH-NR a R b ; R 2 is an amino protecting group; Each R a and R b are independently H or an amino protecting group, or R a , R b Together with the N atom to which they are attached, they form a heterocyclic group consisting of 5-6 ring atoms, wherein each heterocyclic group consisting of 5-6 ring atoms is independently optionally substituted by 1, 2, 3 or 4 substituents selected from deuterium, hydroxyl, cyano, F, Cl, Br, I, methyl, ethyl, n-propyl, isopropyl, methoxy, ethoxy, 1-propoxy and 2-propoxy; in, Each j is independently 1, 2, 3, 4 or 5.

22. The compound according to claim 21, wherein Z and Y 1 each independently represents H, deuterium, benzyloxycarbonyl, 4-nitrobenzyloxycarbonyl, 4-bromobenzyloxycarbonyl, 4-methoxybenzyloxycarbonyl, biphenylmethoxycarbonyl, 2,2,2-trichloroethoxycarbonyl, 2-(trimethylsilyl)ethoxycarbonyl, allyloxycarbonyl, chloroacetyl, trifluoroacetyl, methoxyacetyl, phenoxyacetyl, benzoyl, 2,2,2-trichloroethyl, 2-trimethylsilylethyl, 1,1-dimethyl-2-propenyl, 3-methyl-3-butenyl, allyl, p-methoxybenzyldiphenylmethyl, tetrahydrofuranyl, methoxymethyl, methylthiomethyl, benzyloxymethyl, 2,2,2-trichloroethoxymethyl, 2-(trimethylsilyl)ethoxymethyl, methylsulfonyl, p-toluenesulfonyl, C 1-12 Alkyl, C 1-12 Alkyl C(=O)-, C 1-12 Alkylsilyl, C 6-10 Aryl C 1-6 Alkyl, HOC(=O)(CH2) j C(=O)-、MC(=O)(CH2) j C(=O)-, triphenylmethyl, MMTr, DMTr, 4',4',4'-trimethoxytrityl, or Z and Y 1 each independently represents H, deuterium, benzyloxycarbonyl, 4-nitrobenzyloxycarbonyl, 4-bromobenzyloxycarbonyl, 4-methoxybenzyloxycarbonyl, biphenylmethoxycarbonyl, 2,2,2-trichloroethoxycarbonyl, 2-(trimethylsilyl)ethoxycarbonyl, allyloxycarbonyl, chloroacetyl, trifluoroacetyl, methoxyacetyl, phenoxyacetyl, benzoyl, 2,2,2-trichloroethyl, 2-trimethylsilylethyl, 1,1-dimethyl-2-propenyl, 3-methyl-3-butenyl, allyl, p-methoxybenzyldiphenylmethyl, tetrahydrofuranyl, methoxymethyl, methylthiomethyl, benzyloxymethyl, 2,2,2-trichloroethoxymethyl, 2-(trimethylsilyl)ethoxymethyl, methylsulfonyl, p-toluenesulfonyl, C 1-10 Alkyl, C 1-10 Alkyl C(=O)-, C 1-10 Alkylsilyl, C 6-10 Aryl C 1-4 Alkyl, HOC(=O)(CH2) j C(=O)-、MC(=O)(CH2) j C(=O)-, triphenylmethyl, MMTr, DMTr, 4',4',4'-trimethoxytrityl, or Z and Y 1 are each independently H, deuterium, benzyloxycarbonyl, 4-nitrobenzyloxycarbonyl, 4-bromobenzyloxycarbonyl, 4-methoxybenzyloxycarbonyl yl, biphenyl methoxycarbonyl, 2,2,2-trichloroethoxycarbonyl, 2-(trimethylsilyl)ethoxycarbonyl, allyloxycarbonyl, chloroacetyl, trifluoroacetyl, methoxyacetyl, phenoxyacetyl, benzoyl, 2,2,2-trichloroethyl, 2-trimethylsilylethyl, 1,1-dimethyl-2-propenyl, 3-methyl-3-butenyl, allyl, p-methoxybenzyldiphenylmethyl, tetrahydrofuranyl, methoxymethyl, methylthiomethyl, benzyloxymethyl, 2,2,2-trichloroethoxymethyl, 2-(trimethylsilyl)ethoxymethyl, methylsulfonyl, p-toluenesulfonyl, C 1-8 Alkyl, C 1-8 Alkyl C(=O)-, C 1-8 Alkylsilyl, phenyl C 1-3 Alkyl, HOC(=O)(CH2) j C(=O)-、MC(=O)(CH2) j C(=O)-, triphenylmethyl, MMTr, DMTr, 4',4',4'-trimethoxytrityl, or Z and Y 1 each independently represents H, deuterium, benzyloxycarbonyl, 4-nitrobenzyloxycarbonyl, 4-bromobenzyloxycarbonyl, 4-methoxybenzyloxycarbonyl, biphenylmethoxycarbonyl, 2,2,2-trichloroethoxycarbonyl, 2-(trimethylsilyl)ethoxycarbonyl, allyloxycarbonyl, chloroacetyl, trifluoroacetyl, methoxyacetyl, phenoxyacetyl, benzoyl, 2,2,2-trichloroethyl, 2-trimethylsilylethyl, 1,1-dimethyl-2-propenyl, 3-methyl-3-butenyl, allyl, p-methoxybenzyldiphenylmethyl, tetrahydrofuranyl, methoxymethyl, methylthiomethyl, benzyloxymethyl, 2,2,2-trichloroethoxymethyl, 2-(trimethylsilyl)ethoxymethyl, methylsulfonyl, p-toluenesulfonyl, C 1-6 Alkyl, C 1-6 Alkyl C(=O)-, C 1-6 Alkylsilyl, benzyl, phenethyl, HOC(=O)(CH2) j C(=O)-、MC(=O)(CH2) j C(=O)-, triphenylmethyl, MMTr, DMTr, 4',4',4'-trimethoxytrityl, Wherein, X is Cl or Br; Each R x and R y are independently a hydroxy protecting group; Each R c and R d are independently H or an amino protecting group; or R c , R d Together with the N atom to which they are attached, they form a heterocyclic group consisting of 5-6 ring atoms, and the heterocyclic group consisting of 5-6 ring atoms is independently optionally substituted by 1, 2, 3 or 4 substituents selected from deuterium, hydroxyl, cyano, F, Cl, Br, I, methyl, ethyl, propyl, methoxy, ethoxy, 1-propoxy and 2-propoxy.

23. The compound according to claim 21 or 22, wherein R 2 is 9-fluorenylmethoxycarbonyl, benzyloxycarbonyl, 4-nitrobenzyloxycarbonyl, 4-bromobenzyloxycarbonyl, 4-methoxybenzyloxycarbonyl, biphenylmethoxycarbonyl, 2,2,2-trichloroethoxycarbonyl, 2-(trimethylsilyl)ethoxycarbonyl, allyloxycarbonyl, chloroacetyl, trifluoroacetyl, methoxyacetyl, phenoxyacetyl, benzoyl, methyl, tert-butyl, 2-trimethylsilylethyl, 1,1-dimethyl-2-propenyl, 3-methyl-3-butenyl, allyl, benzyl, p-methoxybenzyldiphenylmethyl, trityl, tetrahydrofuranyl, methoxymethyl, methylthiomethyl, benzyloxymethyl, 2,2,2-trichloroethoxymethyl, 2-(trimethylsilyl)ethoxymethyl, methylsulfonyl, p-toluenesulfonyl, trimethylsilyl, triethylsilyl, triisopropylsilyl, C 1-6 Alkoxy or R 3 C(=O)-; Each R a and R b are independently H, methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, tert-butyl, methoxy, ethoxy, 1-propoxy, 2-propoxy, 9-fluorenylmethoxycarbonyl, benzyloxycarbonyl, 4-nitrobenzyloxycarbonyl, 4-bromobenzyloxycarbonyl, 4-methoxybenzyloxycarbonyl, biphenylmethoxycarbonyl, 2,2,2-trichloroethoxycarbonyl, 2-(trimethylsilyl)ethoxycarbonyl, allyloxycarbonyl, chloroacetyl, trifluoroacetyl, methoxyacetyl, phenoxyacetyl, benzoyl, 2-trimethylsilylethyl, 1,1-dimethyl-2-propenyl, 3-methyl-3-butenyl, allyl, benzyl, p-methoxybenzyldiphenylmethyl, trityl, tetrahydrofuranyl, methoxymethyl, methylthiomethyl, benzyloxymethyl, 2,2,2-trichloroethoxymethyl, 2-(trimethylsilyl)ethoxymethyl, methanesulfonyl, p-toluenesulfonyl, trimethylsilyl, triethylsilyl, triisopropylsilyl or R 4 C(=O)-, or R a , R b and together with the N atom to which they are attached form a pyrrolidinyl, morpholinyl, piperidinyl or piperazinyl, said pyrrolidinyl, morpholinyl, piperidinyl and or piperazinyl being each independently optionally substituted with 1, 2, 3 or 4 substituents selected from deuterium, hydroxyl, cyano, F, Cl, Br, I, methoxy, ethoxy, 1-propoxy and 2-propoxy; Among them, each R 3 and R 4 Independently for C 1-6 Alkyl, halogenated C 1-6 Alkyl, C 1-6 Alkoxy, phenyl, halogen-substituted phenyl, C 1-6 alkyl phenyl or benzyl; or Each R 3 and R 4 Independently for C 1-4 Alkyl, halogenated C 1-4 Alkyl, C 1-4 Alkoxy, phenyl, halogen-substituted phenyl, C 1-4 Alkylphenyl or benzyl; or Each R 3 and R 4 are independently methyl, ethyl, n-propyl, isopropyl, trifluoromethyl, difluoromethyl, monofluoromethyl, trichloromethyl, dichloromethyl, monochloromethyl, 2,2,2-trichloroethyl, methoxy, ethoxy, 1-propoxy, 2-propoxy, 1-butoxy, 2-methyl-1-propoxy, 2-butoxy, tert-butoxy, phenyl, halogen-substituted phenyl, C 1-3 Alkylphenyl or benzyl.

24. According to any one of claims 22-23, each R x and R y are independently benzyloxycarbonyl, 4-nitrobenzyloxycarbonyl, 4-bromobenzyloxycarbonyl, 4-methoxybenzyloxycarbonyl, biphenylmethoxycarbonyl, 2,2,2-trichloroethoxycarbonyl, 2-(trimethylsilyl)ethoxycarbonyl, allyloxycarbonyl, chloroacetyl, trifluoroacetyl, methoxyacetyl, phenoxyacetyl, benzoyl, 2,2,2-trichloroethyl, 2-trimethylsilylethyl, 1,1-dimethyl-2-propenyl, 3-methyl-3-butenyl, allyl, p-methoxybenzyldiphenylmethyl, tetrahydrofuranyl, methoxymethyl, methylthiomethyl, benzyloxymethyl, 2,2,2-trichloroethoxymethyl, 2-(trimethylsilyl)ethoxymethyl, methylsulfonyl, p-toluenesulfonyl, cyano C 1-6 Alkyl, C 1-6 Alkyl, C 1-6 Alkyl C(=O)-, C 1-6 Alkylsilyl, phenyl, halogen-substituted phenyl, benzyl or phenethyl; or Each R x and R y are independently benzyloxycarbonyl, 4-nitrobenzyloxycarbonyl, 4-bromobenzyloxycarbonyl, 4-methoxybenzyloxycarbonyl, biphenylmethoxycarbonyl, 2,2,2-trichloroethoxycarbonyl, 2-(trimethylsilyl)ethoxycarbonyl, allyloxycarbonyl, chloroacetyl, trifluoroacetyl, methoxyacetyl, phenoxyacetyl, benzoyl, 2,2,2-trichloroethyl, 2-trimethylsilylethyl, 1,1-dimethyl-2-propenyl, 3-methyl-3-butenyl, allyl , p-methoxybenzyldiphenylmethyl, tetrahydrofuranyl, methoxymethyl, methylthiomethyl, benzyloxymethyl, 2,2,2-trichloroethoxymethyl, 2-(trimethylsilyl)ethoxymethyl, methanesulfonyl, p-toluenesulfonyl, CNCH2-, CN(CH2)2-, CNCH(CH3)2CH2-, CN(CH2)3-, CNCH(CH3)2CH2CH2-, methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, tert-butyl, , C 1-4 Alkyl C(=O)-, C 1-4 Alkylsilyl, phenyl, halogen-substituted phenyl, benzyl or phenethyl; Each R c and R d and 1-(2-(4-(6-methyl-1-thio)-1-yl)- ... acetyl, benzoyl, 2-trimethylsilylethyl, 1,1-dimethyl-2-propenyl, 3-methyl-3-butenyl, allyl, benzyl, p-methoxybenzyldiphenylmethyl, trityl, tetrahydrofuranyl, methoxymethyl, methylthiomethyl, benzyloxymethyl, 2,2,2-trichloroethoxymethyl, 2-(trimethylsilyl)ethoxymethyl, methanesulfonyl, p-toluenesulfonyl, trimethylsilyl, triethylsilyl, triisopropylsilyl or R 4 C(=O)-, or R c , R d Together with the N atom to which they are attached, they form a pyrrolidinyl, morpholinyl, piperidinyl or piperazinyl group, each of which is independently optionally substituted with 1, 2, 3 or 4 substituents selected from deuterium, hydroxyl, cyano, F, Cl, Br, I, methoxy, ethoxy, 1-propoxy and 2-propoxy.

25. A compound according to any one of claims 21 to 24, having a structure as shown in formula (II), 26. A pharmaceutical composition comprising the double-stranded siRNA, its conjugate or salt thereof according to any one of claims 1 to 19, and a pharmaceutically acceptable carrier.

27. Use of the double-stranded siRNA conjugate, its conjugate and salt thereof according to any one of claims 1 to 19 or the pharmaceutical composition according to claim 26 in the preparation of a medicament for treating and / or preventing hepatitis B disease.

28. Use of the compound according to any one of claims 21 to 25 in raw materials for solid phase synthesis of DNA nucleotides, raw materials for synthesis of oligonucleotide drugs, raw materials for synthesis of siRNA drugs, siRNA drug research, gene function research and / or screening of whole gene libraries.

29. Use of the nucleotide residue as claimed in claim 20 as an oligonucleotide intercalating group, wherein: The oligonucleotide is a nucleotide sequence containing 10 to 50 nucleotides or nucleotide base pairs, and the oligonucleotide can inhibit or block the expression of a gene.

30. The use according to claim 29, wherein: The gene is the HBV gene.

31. The use according to claim 29 or 30, wherein: The oligonucleotide is siRNA.

32. The use according to any one of claims 31, wherein: The siRNA includes a sense strand and an antisense strand.

33. The use according to claim 32, wherein: The nucleotide residues are incorporated only into the sense strand of the siRNA.

34. The use according to claim 32 or 33, wherein: The nucleotide residues are incorporated only into the antisense strand of the siRNA.

35. The use according to any one of claims 32 to 34, wherein: The nucleotide residues are incorporated into the sense and antisense strands of the siRNA.

36. The use according to any one of claims 32 to 35, wherein: The sense strand of the siRNA comprises the sequence shown in SEQ ID NO:

19.

37. The use according to any one of claims 32 to 36, wherein: The antisense strand of the siRNA comprises the sequence shown in SEQ ID NO:36 or SEQ ID NO:

33.

38. The double-stranded siRNA conjugate, its conjugate and salt thereof according to any one of claims 1 to 19 or the pharmaceutical composition according to claim 26 for use in treating and / or preventing hepatitis B disease.

39. The compound according to any one of claims 21 to 25 is used as a raw material for solid phase synthesis of DNA nucleotides, a raw material for the synthesis of oligonucleotide drugs, a raw material for the synthesis of siRNA drugs, siRNA drug research, gene function research and / or screening of a whole gene library.

40. The nucleotide residue of claim 20, which is used as an oligonucleotide intercalating group, wherein: The oligonucleotide is a nucleotide sequence containing 10 to 50 nucleotides or nucleotide base pairs, and the oligonucleotide can inhibit or block the expression of a gene.

41. The nucleotide residue according to claim 40, wherein The gene is the HBV gene.

42. The nucleotide residue according to claim 40 or 41, wherein The oligonucleotide is siRNA.

43. The nucleotide residue according to any one of claims 42, wherein The siRNA includes a sense strand and an antisense strand.

44. The nucleotide residue according to claim 43, wherein The nucleotide residues are incorporated only into the sense strand of the siRNA.

45. The nucleotide residue according to claim 43 or 44, wherein The nucleotide residues are incorporated only into the antisense strand of the siRNA.

46. ​​The nucleotide residue according to any one of claims 43 to 45, wherein The nucleotide residues are incorporated into the sense and antisense strands of the siRNA.

47. The nucleotide residue according to any one of claims 43 to 46, wherein The sense strand of the siRNA comprises the sequence shown in SEQ ID NO:

19.

48. The nucleotide residue according to any one of claims 43 to 47, wherein The antisense strand of the siRNA comprises the sequence shown in SEQ ID NO:36 or SEQ ID NO:

33.

49. A method for treating and / or preventing hepatitis B disease, the method comprising using the double-stranded siRNA conjugate, its conjugate and its salt according to any one of claims 1 to 19 or the pharmaceutical composition according to claim 26.

50. A method for solid phase synthesis of DNA nucleotides, synthesis of oligonucleotide drugs, synthesis of siRNA drugs, siRNA drug research, gene function research and / or screening of a whole gene library, the method comprising using the compound described in any one of claims 21-25.

51. A method for inhibiting or blocking gene expression, the method comprising using a nucleotide sequence comprising 10 to 50 nucleotides or nucleotide base pairs, wherein the nucleotide sequence has the nucleotide residues according to claim 20 embedded therein.

52. The method of claim 51, wherein: The gene is the HBV gene.

53. The method according to claim 51 or 52, wherein: The oligonucleotide is siRNA.

54. The method according to any one of claims 53, wherein: The siRNA includes a sense strand and an antisense strand.

55. The method of claim 54, wherein: The nucleotide residues are incorporated only into the sense strand of the siRNA.

56. The method of claim 54 or 55, wherein: The nucleotide residues are incorporated only into the antisense strand of the siRNA.

57. The method according to any one of claims 54 to 56, wherein: The nucleotide residues are incorporated into the sense and antisense strands of the siRNA.

58. The method according to any one of claims 54 to 57, wherein: The sense strand of the siRNA comprises the sequence shown in SEQ ID NO:

19.

59. The method according to any one of claims 54 to 58, wherein: The antisense strand of the siRNA comprises the sequence shown in SEQ ID NO:36 or SEQ ID NO:33.

Citation Information

Patent Citations

  • Methods of treating APOC3 related diseases and disorders

    CN114555188A

  • Carbohydrate conjugated RNA agents and process for their preparation

    WO2014025805A1

  • Oligonucleotide-ligand conjugates and process for their preparation

    WO2015006740A2

  • HEPATITIS B VIRUS (HBV) dsRNA AGENT COMPOSITIONS AND METHODS OF USE THEREOF

    CN112673103A

  • Application of nucleoside analogue or combined preparation containing nucleoside analogue in virus resistance

    CN112778310A

Cited By

  • Novel double-stranded siRNA (small interfering ribonucleic acid) as well as conjugate and application thereof

    CN122103208A